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ABSTRACT 
Type 2 diabetes results from the interaction between genetic predisposition and unhealthy lifestyle. 
Increasing physical activity may protect against the development of type 2 diabetes, but genetic factors 
likely influence the response to physical activity. The interactions between physical activity and genes in 
the development of type 2 diabetes are poorly understood. The main aim of the present study was to 
investigate interactions between physical activity and genes in the etiology of type 2 diabetes in the 
Finnish Diabetes Prevention Study (DPS).  
   The DPS is a multicentre randomized controlled trial on the effects of a multi-component (physical 
activity, diet, weight reduction) lifestyle intervention on the risk of developing type 2 diabetes among 522 
overweight individuals with impaired glucose tolerance (IGT). In the DPS, changes in physical activity 
were a strong predictor of the risk of type 2 diabetes independent of changes in diet and body weight. 
Several genetic polymorphisms have also been associated with the risk of developing type 2 diabetes. For 
many of the genes, the polymorphisms had effects predominantly in either the intervention or control 
group, indicating a gene-lifestyle interaction.   
   In the present study, interactions between physical activity and genes were investigated by secondary 
analyses of the DPS data. The associations of the rs17036314 and rs1801282 (Pro12Ala) single–
nucleotide polymorphisms (SNPs) in the PPARG gene with the progression from IGT to type 2 diabetes 
were modified by changes in physical activity during the intervention. Increased physical activity seemed 
to remove the harmful effect of the risk alleles (Pinteraction=0.002 and 0.031 for rs17036314 and rs1801282, 
respectively). Similarly, changes in physical activity modified the associations of the rs5393, rs5394, and 
rs5400 SNPs in the SLC2A2 gene and the association of the rs3758947 SNP in the ABCC8 gene with the 
risk of type 2 diabetes. Physical activity attenuated the effect of the risk genotypes on the risk of 
developing type 2 diabetes (Pinteraction=0.022-0.027 for SNPs in SLC2A2 and Pinteraction=0.008 for 
rs3758947). Furthermore, the rs696217 (Leu72Met) SNP in the GHRL gene modified the effect of 
physical activity on changes in body weight and waist circumference, the rs26802 SNP in the GHRL gene 
modified the effect of physical activity on changes in serum high density lipoprotein cholesterol, the 
rs1137100 (Lys109Arg) SNP in the LEPR gene modified the effect of physical activity on changes in 
systolic blood pressure, and the rs1800795 SNP in the TNF gene modified the effect of physical activity 
on changes in serum C-reactive protein. The beneficial effects of increased physical activity were only 
seen in the carriers of specific genotypes of these SNPs. 
   These secondary analyses of the Finnish DPS indicate that variation in genes regulating both insulin 
sensitivity (PPARG) and insulin secretion (SLC2A2, ABCC8) interact with changes in physical activity on 
the risk of developing type 2 diabetes. Furthermore, variation in the LEPR and GHRL genes may modify 
the effects of physical activity on changes in features of metabolic syndrome, and variation in the TNF 
gene may modify the effect of physical activity on changes in serum CRP levels. However, replication in 
independent study populations is necessary to confirm the findings. 
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ABBREVIATIONS
A  adenine 
ABCC8 ATP-binding cassette, sub-
family C, member 8 
ACE angiotensin I converting 
enzyme 1  
ADAMTS9 ADAM metallopeptidase with 
thrombospondin type 1 motif 9 
ADRA2B adrenergic receptor alpha-2B 
ADRB2  adrenergic receptor beta-2 
ADRB3  adrenergic receptor beta-3 
Ala  alanine 
ANOVA analysis of variance 
Arg  arginine 
ATP  adenosine triphosphate 
AUC  area under the curve 
BMI  body mass index 
bp  base pair(s) 
C  cytosine 
CAMK1D calcium/calmodulin-dependent 
protein kinase 1D 
CAP1 adenylate cyclase-associated 
protein 1 
CDC123 cell division cycle 123 
homologue 
CDKAL1 CDK5 regulatory subunit-
associated protein 1-like 1 
CDKN2B cyclin-dependent kinase 
inhibitor 2B 
CI  confidence interval 
COMT  catechol O-methyltransferase 
CRP  C-reactive protein 
CYP19 cytochrome P450, family 19, 
subfamily A 
DNA  deoxyribonucleic acid 
DPP  Diabetes Prevention Program 
DPS  Diabetes Prevention Study 
E  glutamic acid 
ELISA enzyme-linked immunosorbent 
assay 
EXT2  exostoses 2 
FFA  free fatty acid 
FSIGT frequently sampled intravenous 
glucose tolerance test 
FTO  fat mass and obesity associated 
G  guanine 
GH  growth hormone 
GHRL ghrelin/obestatin 
preprohormone 
Gln  glutamine 
Glu  glutamic acid 
GLUT2  glucose transporter isoform 2 
GLUT4  glucose transporter isoform 4 
Gly  glycine 
GNB3 guanine nucleotide binding 
protein, beta polypeptide 3 
HDL  high density lipoprotein 
HERITAGE Health, Risk Factors, Exercise 
Training, and Genetics  
HHEX haematopoietically expressed 
homeobox 
His  histidine 
HNF1B hepatocyte nuclear factor 1 
homeobox B 
I/D  insertion/deletion 
IDE  insulin degrading enzyme 
IFG  impaired fasting glucose 
IGF1R insulin–like growth factor 1 
receptor 
IGF2BP2 insulin-like growth factor 2 
mRNA binding protein 2 
IGT  impaired glucose tolerance 
IL6  interleukin-6 gene 
IL-6  interleukin-6 
JAZF1 juxtaposed with another zinc 
finger gene 1 
   
 
K  lysine 
KATP ATP–sensitive potassium 
channel 
KCNJ11 potassium inwardly rectifying 
channel, subfamily J, member 
11 
KIHD Kuopio Ischaemic Heart 
Disease Risk Factor Study 
Kir6.2 inwardly rectifying potassium 
channel 
LDL  low density lipoprotein 
LEP  leptin 
LEPR  leptin receptor 
Leu  leucine 
LIPC  hepatic lipase 
LPL  lipoprotein lipase 
Lys  lysine 
MAF  minor allele frequency 
Met  metionine 
MET metabolic equivalent of oxygen 
consumption 
NCBI National Center for 
Biotechnology Information 
NO  nitric oxide 
NOS3 nitric oxide synthase 3 
(endothelial cell) 
OGTT  oral glucose tolerance test 
OR  odds ratio 
PCR  polymerase chain reaction 
PPARG peroxisome proliferator-
activated receptor gamma gene 
PPARγ peroxisome proliferator-
activated receptor gamma 
Pro  proline 
RFLP restriction fragment length 
polymorphism 
RNA  ribonucleic acid 
RR  relative risk 
S  serine 
SBP  systolic blood pressure 
SD  standard deviation 
SLC2A2 solute carrier family 2 
(facilitated glucose transporter) 
member 2 
SLC30A8 solute carrier family 30 (zinc 
transporter), member 8 
SNP single nucleotide 
polymorphism 
SSCP single-strand conformation 
polymorphism 
SUR1  sulfonylurea receptor 1 
T  thymine 
TCF7L2 transcription factor 7 like 2 
THADA  thyroid adenoma associated 
TNF tumor necrosis factor alpha 
gene 
TNF-alpha tumor necrosis factor-alpha 
TNMD  tenomodulin 
Trp  tryptophan 
TSPAN8 tetraspanin  
Val  valine 
VDR vitamin D (1,25-
dihydroxyvitamin D3) receptor 
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VO2max maximal oxygen uptake 
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I INTRODUCTION 
 
Type 2 diabetes is one of the severest public health problems worldwide [1]. It is a common 
metabolic disease with a rapidly increasing prevalence in both developed and developing 
countries [2]. The micro- and macrovascular complications of diabetes, such as renal 
failure, retinopathy, neuropathy and cardiovascular disease create a large amount of human 
suffering [3]. Furthermore, while type 2 diabetes was previously considered essentially a 
disease of middle-aged and older individuals, it is now emerging as a new serious health 
problem in children [4]. As the worldwide epidemic of type 2 diabetes threatens to increase 
the burden on health care systems dramatically worldwide, the prevention of type 2 
diabetes has become a major challenge for clinicians and public health policy makers all 
over the world. 
     To prevent type 2 diabetes, it is important to gain knowledge on the factors that 
contribute to its development. The strong familial clustering of type 2 diabetes points to the 
important role of genetic mechanisms [5,6]. However, the recent rapid changes in diabetes 
prevalence, which could not have emerged for genetic reasons, indicate that environmental 
and lifestyle factors are also of major relevance [7]. Indeed, type 2 diabetes seems to 
develop as the result of a complex interaction between genes and lifestyle, where numerous 
susceptibility genes combined with an unhealthy lifestyle gradually lead to the development 
of manifest disease [8]. 
     Physical inactivity is an important risk factor for type 2 diabetes, whereas increased 
physical activity is protective [9]. However, the magnitude of responses to regular physical 
activity differs considerably among individuals. With regard to any component of health-
related fitness such as maximal oxygen uptake (VO2max), blood pressure, heart rate, and 
high-density lipoprotein (HDL) cholesterol, there seems to be high-responders, low-
responders, and even non-responders to exercise interventions in the population [10]. A 
large part of such inter-individual variability may be explained by genetic differences 
[10,11]. Individuals with specific genetic profiles are also expected to be more responsive 
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to the beneficial effects of physical activity in the prevention of type 2 diabetes. At present, 
however, it is not known which key genetic factors modify the individual responses to 
physical activity. Such information would be important, as it would increase understanding 
of the disease etiology, and might lead to the development of better therapies. Furthermore, 
such knowledge could make it possible to identify the individuals and groups who are at 
increased risk of type 2 diabetes, and to identify those individuals who have the potential to 
benefit most from a targeted lifestyle prevention [12]. 
     The study of gene–physical activity interactions is challenging. Firstly, most gene 
variants associated with common disease have only modest effects [13,14]. Secondly, 
lifestyle factors such as physical activity are difficult to quantify precisely [15-17]. Thirdly, 
several lifestyle and environmental factors confound the analyses. Therefore, the detection 
of gene–physical activity interactions requires large study populations and careful 
measurement of lifestyle and environmental exposures. 
     Because of careful collection of data on lifestyle and phenotype and the genotyping of 
numerous genetic polymorphisms, the Finnish Diabetes Prevention Study (DPS) provides 
an excellent possibility to investigate interactions between genes and lifestyle in a 
prospective study setting. The main aim of the present study was to investigate how 
physical activity and genes interact in the development of type 2 diabetes in the high-risk 
population sample of the DPS. 
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II REVIEW OF THE LITERATURE 
 
TYPE 2 DIABETES 
 
Definition 
Type 2 diabetes is a common disease, primarily characterized by an increased level of 
plasma glucose. In contrast to type 1 diabetes where insulin secretion from the pancreatic 
β–cells is lost, type 2 diabetes is the result of concomitant defects in insulin secretion and 
peripheral insulin sensitivity, the latter being typically associated with obesity [1,18]. 
Because insulin regulates glucose uptake into tissues and the release of stored fatty acids, 
defects in insulin action and secretion will cause chronic increase in blood glucose levels 
(hyperglycemia) and impaired lipid and lipoprotein metabolism (dyslipidemia) [19]. These 
may further impair insulin secretion and action, and in the long run, lead to severe micro- 
and macrovascular complications such as renal failure, neuropathy, retinopathy, and 
cardiovascular disease [3,20]. The avoidance of such hyperglycemia-related complications 
is the underlying rationale behind the diagnostic criteria of type 2 diabetes (Table 1). The 
diagnosis can be based on the measurement of fasting plasma glucose or the measurement 
of 2-hour glucose after ingestion of 75 g oral glucose (Table 1). Apart from type 2 diabetes, 
impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are commonly 
defined (Table 1). Both IGT and IFG are associated with an increased risk of type 2 
diabetes, and about 30% of individuals with IGT develop type 2 diabetes in 10 years [21]. 
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Table 1. The World Health Organization (1999) diagnostic criteria of type 2 diabetes, impaired fasting 
glucose (IFG), and impaired glucose tolerance (IGT) [1,18]. 
 Fasting plasma glucose (mmol/L)     2-h plasma glucose (mmol/L)¹ 
Normoglycemia <6.1 and <7.8 
IFG ≥6.1 and <7.0 and <7.8 
IGT <7.0 and ≥7.8 and <11.1 
Diabetes ≥7.0 or ≥11.1 
¹2 hours after ingestion of 75 g oral glucose  
 
Prevalence and environmental risk factors 
Type 2 diabetes is one of the leading health problems in the developed world, and is 
becoming increasingly important in the developing world. The worldwide prevalence was 
171 million in 2000, but the number is projected to reach 366 million by 2030 [2]. 
Furthermore, although most cases of type 2 diabetes are diagnosed after the age of 40, 
diabetes is becoming increasingly common among the younger age groups [4,22,23]. The 
increasing worldwide prevalence of type 2 diabetes combined with the shift in its age of 
onset will heavily burden health-care systems in the future. 
     The causes of the rapid spread of type 2 diabetes are incompletely understood. However, 
it is known that the genetic pool of human population changes slowly. New genetic 
polymorphisms fixate gradually and are estimated to become balanced in no less than 5,000 
years [24]. Epigenetic modifications where changes in chromatin structure occur without 
changes in nucleotide sequence, can take place within a relatively short time frame and may 
result in altered gene expression. Nonetheless, it is still controversial how extensively 
epigenetic changes are transmitted to future generations [25,26]. It is thus likely that 
genetic changes do not substantially account for the rapid increase in the prevalence of type 
2 diabetes [7], and that the main causes of the diabetes-epidemic are environmental. In 
particular, the epidemic of type 2 diabetes correlates with the recent explosion in the 
prevalence of obesity [27]. Indeed, both observational and randomized trial data indicate 
that overweight and obesity defined as a body mass index (BMI) of greater than 25 kg/m
2
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and 30 kg/m
2
, respectively, increase the risk of type 2 diabetes [27]. The risk rises steadily 
above low levels of BMI, but exponentially above a BMI of 30 kg/m
2
. Women with BMI 
between 23 and 25 kg/m
2
 have an almost three-fold increased risk of developing diabetes 
compared with women with a BMI below 23 kg/m
2
 [28]. This relative risk increases to 20 
for women with BMI ≥35 kg/m2 [28]. In men at BMI >35 kg/m2, the risk is around 40-fold 
compared with a BMI <23 kg/m
2
 [29]. 
     Sedentary lifestyle is another important risk factor for type 2 diabetes [9]. Physical 
inactivity increases the risk of weight gain [30], but has additional effects beyond the 
regulation of body weight [9]. Similarly, unhealthy diet, including low 
unsaturated/saturated fat intake ratio [31], high glycemic-index or glycemic load of diet 
[32-34], and low fiber intake [35] increases the risk. Smoking is also associated with an 
increased risk [36], whereas consumption of coffee [37] and moderate use of alcohol [38] 
are protective. 
     Age, gender, prior gestational diabetes or glucose intolerance, and low-birth weight 
especially if followed by rapid growth in childhood, are non-mofidiable risk factors for type 
2 diabetes [39,40]. The risk of type 2 diabetes increases with age, and the peak age of onset 
is 60-70 years [22,23]. The risk is slightly higher among men than women, but because 
women have longer life expectancy there are more diabetic women than men in the world 
[41]. 
 
Pathogenesis 
The current evidence suggests that obesity and unhealthy lifestyle exert their deleterious 
effects on glucose homeostasis mainly by increasing insulin resistance of peripheral tissues 
[42-45]. Visceral obesity in particular is closely related with insulin resistance, and is 
thought to be the core feature of the metabolic syndrome, characterized by insulin 
resistance, dyslipidemia, and hypertension [46-48]. The key role of visceral fat in the 
development of insulin resistance and related metabolic disturbances may partly be related 
with its high metabolic activity [43], but also its anatomical location right next to the 
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hepatic portal circulation is likely to be important [49]. The unhindered entry of fatty acids 
from visceral fat to the liver leads to an elevation in hepatic triglyceride synthesis, which 
decreases liver insulin sensitivity and subsequently increases hepatic glucose production 
[50,51]. Apart from fatty acids, adipocytes in visceral fat and elsewhere are known to 
excrete a multitude of hormones and cytokines (adipokines), such as adiponectin, tumor 
necrosis factor-α (TNF-α) and interleukin-6 (IL-6), which may modify insulin signaling and 
contribute to the systemic low-grade chronic inflammation that characterizes the 
development of insulin resistance and type 2 diabetes [20,52-56]. 
     Similarly with liver, increased circulating levels of fatty acids and adipokines may cause 
insulin resistance in the skeletal muscle [42]. Skeletal muscle has a central role in the 
regulation of glucose homeostasis, because it is the main tissue responsible for insulin-
stimulated glucose uptake [57]. High levels of circulating fatty acids decrease muscle 
glucose uptake and increase fatty acid uptake [42]. This imbalance in fat and glucose 
uptake leads to an accumulation of intramyocellular lipid metabolites, which seems to 
disrupt normal insulin signaling cascade and may contribute to mitochondrial dysfunction 
[58-60]. Furthermore, obesity is associated with endothelial dysfunction and impaired 
muscle microcirculation [61-63], which may impair whole-body insulin sensitivity by 
hindering the entry of insulin and glucose into skeletal muscle and decreasing their 
availability to muscle cells [54-56,64-67].  
     Chronic exposure to glucose and fatty acids is detrimental to pancreatic beta-cells and 
may gradually lead to beta-cell failure, involving a partial loss of beta-cell mass and a 
deterioration of beta-cell function [20,43,68-71]  Beta-cell failure is the triggering factor for 
the transition from an obese, insulin-resistant state to full-blown type 2 diabetes [20] 
Although the mechanisms of the beta-cell failure are still incompletely understood, the 
current evidence suggest the failure to be caused by a combined consequence of metabolic 
overload [70], oxidative stress [72], increased rates of beta-cell apoptosis [73], and loss of 
expression of key components of the insulin secretory machinery [74]. 
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Heritability 
Although lifestyle changes generally explain the recent rapid spread of type 2 diabetes, 
there are large differences in the individual susceptibility to develop glucose abnormalities 
when environmental risk factors are present. For example, not all obese people develop 
insulin resistance, and some insulin resistant individuals are able to tolerate insulin 
resistance by augmenting insulin production to overcome the increased demand. Such 
differences are likely due to genetic factors [75,76]. Indeed, strong evidence from both 
family and twin studies indicate that type 2 diabetes is strongly heritable. The risk of type 2 
diabetes increases by 40% if one parent has type 2 diabetes, and by 70% if both parents are 
affected [5,6]. According to twin studies, 60-90% of monozygotic twin pairs become 
concordant for type 2 diabetes [77]. Altogether, genetic susceptibility seems to account for 
around half of total disease susceptibility [78]. 
 
 
GENETIC BACKGROUND OF TYPE 2 DIABETES 
 
Despite the strong heritability of type 2 diabetes, the search for diabetes susceptibility genes 
has long been unsuccessful. The complex etiology of type 2 diabetes has been a challenge 
to geneticists. Type 2 diabetes is a multigenic disease where numerous genes affect the risk 
and many combinations of gene defects exist among diabetic patients [79]. Furthermore, 
the multiple genetic variants interact with various environmental factors in their effect on 
the risk. Indeed, type 2 diabetes has earlier been described as 'a geneticist's nightmare' 
[80,81]. 
 
Linkage scans and candidate gene studies 
Over the past decade human geneticists relied predominantly on two approaches for gene 
discovery: genome-wide linkage scans and candidate gene studies [82]. In the genome-wide 
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linkage approach, the variation in the entire human genome is coarsely screened with 
selected marker variants without a priori assumptions about the importance of specific 
chromosomal regions or genes. The genomic regions shared between diabetic relatives 
more often than expected by chance are then analysed with a denser marker map, and the 
attractive candidate gene is localized [83]. In the candidate gene approach, the 
understanding of the pathophysiology of type 2 diabetes is first used to identify promising 
candidate genes, and variations in these genes are then tested for association with type 2 
diabetes [84]. 
     Although numerous genome-wide linkage scans and candidate gene studies on type 2 
diabetes have been performed, they have produced little unequivocal evidence for common 
gene variants associated with type 2 diabetes. The few robust findings from these studies 
include the E23K variant in the potassium inwardly-rectifying channel, subfamily J, 
member 11 (KCNJ11) gene [85-87], the Pro12Ala variant in the peroxisome proliferator-
activated receptor-gamma (PPARG2) gene [88,89], and variants in the hepatocyte nuclear 
factor 1 homeobox B (HNF1B) [90,91] and Wolfram syndrome 1 (WFS1) genes [92] (Table 
2). However, the vast majority of the detected associations between gene variants and type 
2 diabetes have not been replicated. The main problem was that geneticists have an 
immense number of possible genetic variants to study, but only few are likely to be 
involved in type 2 diabetes. Multiple testing has led to many false positive findings [93].  
 
Genome–wide association studies 
The recent application of the genome-wide association approach in the study of disease 
genetics represents a revolution in the search of diabetes susceptibility genes. In genome-
wide association studies, hundreds of thousands or millions of single nucleotide 
polymorphisms (SNPs), spread across the entire genome, are studied in a single analysis 
[94]. The common variation across the human genome can thus be comprehensively 
covered, allowing the identification of diabetes susceptibility genes at the genome-wide 
level. The most significant genome-wide associations are confirmed by genotyping in 
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independent cohorts. Genome–wide association studies are hypothesis-free and unbiased by 
previous theories concerning candidate genes and pathways. Therefore, they provide the 
opportunity to identify completely unexpected genes, broadening understanding of disease 
mechanisms. The genome-wide association studies are, however, limited by the modest 
effect sizes of common susceptibility variants and multiple testing, which lead to very large 
sample size requirements. On the other hand, large population samples are difficult to 
characterize accurately, which complicates the assessment of gene-environment 
interactions in such studies. 
     In the past two years, several large genome–wide association analyses for type 2 
diabetes have been carried out within case-control studies, uncovering a number of 
previously unsuspected variants (Table 2). Except for the fat mass and obesity associated 
(FTO) gene which increases body weight [95], all the newly found susceptibility genes may 
affect insulin secretion (Table 2). At present, only one susceptibility gene, PPARG2, is 
primarily thought to affect insulin resistance [96]. Indeed, an etiological model has now 
been suggested where type 2 diabetes emerges when environmentally triggered insulin 
resistance takes place in the context of genetically programmed β–cell dysfunction [44]. 
However, still many more susceptibility loci have to be identified as only a small fraction 
of heritability can be explained by the known variants [14]. Genome-wide association 
studies are limited by the modest effect sizes of common susceptibility variants and 
multiple testing, and it has not yet been possible to detect rare susceptibility variants for 
type 2 diabetes [97]. Furthermore, other forms of genetic variation than SNPs, including 
copy number variation, micro-RNAs, and epigenetic mechanisms, may modify the risk of 
type 2 diabetes [14]. Future efforts are likely to be directed towards other types of genetic 
variation and towards rarer variants in general [13]. 
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Table 2. Single nucleotide polymorphisms (SNPs) with confirmed association with the risk of  type 2 
diabetes in genome-wide association studies, large-scale association studies or robust candidate gene 
studies 
SNP Nearest Genes Probable Mechanism OR References 
rs7901695 TCF7L2 β–cell dysfunction 1.37 [98-101] 
rs2237892 KCNQ1 β–cell dysfunction 1.29 [102,103] 
rs10811661 CDKN2A/2B β–cell dysfunction 1.20 [100,104,105] 
rs8050136 FTO Altered body mass index 1.17 [100,106] 
rs1111875 HHEX/IDE β–cell dysfunction 1.15 [100,101,101,104,105] 
rs13266634 SLC30A8 β–cell dysfunction 1.15 [100,101,101,104,105] 
rs7578597 THADA Unknown 1.15 [107] 
rs1801282  PPARG2 Insulin resistance 1.14 [89,100] 
rs5215 KCNJ11 β–cell dysfunction 1.14 [86,100] 
rs10946398 CDKAL1 β–cell dysfunction 1.14 [99,100,104,105] 
rs4402960 IGF2BP2 β–cell dysfunction 1.14 [100,104,105] 
rs10923931 NOTCH2 Unknown 1.13 [107] 
rs10010131 WFS1 Unknown 1.12 [92,108] 
rs12779790 CDC123/CAMK1D Unknown 1.11 [107] 
rs757210 HNF1B Unknown 1.10 [91] 
rs864745 JAZF1 β–cell dysfunction 1.10 [107] 
rs7961581 TSPAN8/LGR5 Unknown 1.09 [107] 
rs4607103 ADAMTS9 Unknown 1.09 [107] 
Abbreviations: ADAMTS9, ADAM metallopeptidase with thrombospondin type 1 motif 9; CAMK1D, 
calcium/calmodulin-dependent protein kinase 1D; CDC123, cell division cycle 123 homologue; CDKAL1, 
CDK5 regulatory subunit-associated protein 1-like 1; CDKN2A, cyclin-dependent kinase inhibitor 2A; 
FTO, fat mass and obesity associated; HHEX, haematopoietically expressed homeobox; HNF1B, 
hepatocyte nuclear factor 1 homeobox B; IDE, insulin degrading enzyme; IGF2BP2, insulin-like growth 
factor 2 mRNA binding protein 2; JAZF1, juxtaposed with another zinc finger gene 1; KCNJ11, potassium 
inwardly rectifying channel, subfamily J, member 11; LGR5, leusine-rich repeat-containing G-protein 
coupled; OR, odds ratio; PPARG2, peroxisome proliferator-activated receptor gamma 2; SLC30A8, 
solute carrier family 30 (zinc transporter), member 8; SNP, single-nucleotide polymorphism; TCF7L2, 
transcription factor 7 like 2; THADA, thyroid adenoma associated; TSPAN8, tetraspanin 8; WFS1, 
Wolfram syndrome 1.  
Loci are sorted by descending order of per-allele effect size. ORs are estimated for European-descent 
samples. 
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Evidence from diabetes prevention trials 
Unlike genome-wide association studies where diabetic cases and their healthy controls are 
compared, large-scale lifestyle intervention studies allow to assess the association of 
genetic variants with the prospective risk of progressing from IGT to type 2 diabetes. 
Furthermore, they allow the investigation of interactions of candidate genes with lifestyle 
changes. Five lifestyle intervention studies have now demonstrated that a combination of 
lifestyle modifications, including increased physical activity, dietary changes, and weight 
reduction, delay the development of type 2 diabetes in individuals with IGT [109-113]. 
Two of these, the Finnish Diabetes Prevention Study (DPS) and the U.S. Diabetes 
Prevention Program (DPP), have also included a systematic analysis for the genetic 
predictors of type 2 diabetes. The DPS enrolled 522 participants and the DPP 3,234 
participants with overweight and impaired glucose tolerance who were randomised to an 
intensive diet and exercise intervention group or a control group. In both DPS and DPP, the 
risk of developing type 2 diabetes was reduced by 58% in the intervention group compared 
to the control group during an average follow-up of around three years [111,112]. Since this 
original finding, several candidate gene studies on the association of gene polymorphisms 
with the progression from IGT to type 2 diabetes have been carried out (Tables 3 and 4). 
 
The Diabetes Prevention Study 
In the DPS, polymorphisms in 14 genes, including PPARG2, tumor necrosis factor-α 
(TNF), interleukin-6 (IL6), adrenergic receptor beta-2 (ADRB2), adrenergic receptor beta-3 
(ADRB3), hepatic lipase (LIPC), insulin-like growth factor 1 receptor (IGF1R), adrenergic 
receptor alpha 2B (ADRA2B), ATP-binding cassette, sub-family C, member 8 (ABCC8), 
solute carrier family member 2 (SLC2A2), leptin receptor (LEPR), ghrelin (GHRL), 
transcription factor 7 like 2 (TCF7L2), and tenomodulin (TNMD), have been associated 
with the risk of developing type 2 diabetes (Table 3). Two of these genes, PPARG2 and 
TCF7L2, have also been confirmed to increase the risk of type 2 diabetes in large-scale 
case-control studies (Table 2). While the Pro12Ala SNP in the PPARG2 gene was 
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associated with an increased risk of developing type 2 diabetes in the DPS [114], the vast 
majority of other studies suggest a protective effect of the Ala12 allele on the risk. 
     With many of the genes associated with type 2 diabetes, the polymorphism have had 
effects predominantly in either the intervention group [115-120] or the control group 
[114,119,121-123] (Table 3). This may indicate a gene-lifestyle interaction, i.e. that the 
lifestyle intervention has modified the association of the genetic variant with the risk of 
type 2 diabetes. However, it must be noticed that in the control group the chance of finding 
a statistically significant association is also a priori higher because there were twice as 
many incident cases of diabetes than in the intervention group of the DPS [111]. A 
statistically significant interaction term between the genotype and the lifestyle intervention 
of the DPS was found for the variants in the TNF, LIPC, and ADRA2B genes 
[115,117,118]. 
 
Table 3. Genes and their single-nucleotide polymorphisms (SNPs) associated with the risk of developing type 2 
diabetes in the Finnish Diabetes Prevention Study (DPS). 
Gene SNP ORtot ptot ORcon pcon ORint pint Reference 
PPARG2
1
 Pro12Ala
 
2.11 0.010 2.36 <0.05 1.90 NS [114] 
TNF G-308A 1.80 0.034 1.12 0.75 4.39 0.006 [115] 
TNF & IL6
2 
C-174G 2.22 0.045 1.25 0.68 6.19 0.001 [115] 
ADRB2 & 
ADRB3
3 
Gln27Glu  
Trp64Arg 
2.34 0.11 1.73 0.10 1.91 0.023 [116] 
LIPC G-250A 2.89 0.037 – 0.51 – 0.001 [117] 
IGF1R
4
 GAG1013GAA
 
– 0.033 – 0.27 – 0.083 [124] 
ADRA2B 12Glu9 – NS 5.17 0.003 0.09 0.049 [118] 
ABCC8 G-2886A 2.69 0.002 2.42 0.017 3.71 0.037 [119] 
 G-1561A 2.08 0.009 1.72 0.30 2.30 0.013 [119] 
 A-1273G 2.27 0.005 1.97 0.055 3.51 0.023 [119] 
 AGG1273AGA 2.00 0.014 3.01 0.002 1.36 0.55 [119] 
 
 
 25 
 
 
Table 3. Continued 
Gene SNP ORtot ptot ORcon pcon ORint pint Reference 
SLC2A2 rs5393 3.04 0.008 5.56 0.003 1.17 0.82 [121] 
 rs5394 2.54 0.026 4.91 0.007 0.85 0.79 [121] 
 rs5400 2.60 0.009 3.78 0.005 1.40 0.58 [121] 
 rs5404 2.57 0.025 5.07 0.005 0.84 0.77 [121] 
LEPR Lys109Arg 1.69 0.069 2.38 0.016 0.88 0.80 [122] 
 Gln223Arg 2.01 0.042 2.33 0.047 1.55 0.47 [122] 
GHRL Leu72Met 0.47 0.016 0.61 0.20 0.28 0.016 [120] 
TCF7L2
5 
rs12255372 1.71 0.18 2.85 0.021 0.61 0.62 [123] 
TNMD rs2073162
6 
– NS – NS – NS [125] 
 rs2073163
6 
– NS – NS – NS [125] 
Abbreviations:  –, not reported; ABCC8, ATP-binding cassette, sub-family C (CTFR/MRP), member 8; ADRAB2, 
adrenergic receptor alpha 2B ;ADRB2, adrenergic receptor beta-2; ADRB3, adrenergic receptor beta-3; DPS, 
Diabetes Prevention Study; GHRL, ghrelin/obestatin prepropeptide; IGF1R, insulin-like growth factor 1 
receptor; IL6, interleukin 6; LEPR, leptin receptor; LIPC, hepatic lipase; NS, non-significant; PPARG2, 
peroxisome proliferator-activated receptor gamma 2; SLC2A2, solute carrier family 2 (facilitated glucose 
transporter), member 2; SNP, single-nucleotide polymorphism; TCF7L2, transcription factor 7 like 2; TNF, 
tumor necrosis factor; TNMD, tenomodulin.  
The footnotes tot, con and int refer to the total study population, control group and intervention group, 
respectively. Genes are presented in the chronological order of publication. 
1
The Ala12 allele increased the risk of type 2 diabetes  in the DPS, contrasting meta-analyses of case-control 
studies where Ala12 was found to be protective [89,126]. 
2
The combination of TNF -308A and IL6 C-174C genotypes was associated with type 2 diabetes. 
3
The combination of ADRB2 Gln27Gln genotype and ADRB3 Arg64 allele was associated with type 2 diabetes. 
4
The heterozygous genotype was associated with type 2 diabetes, but no difference was seen between the rare 
and common homozygous genotypes. 
5
Relative risks shown instead of ORs. 
6
Associated with type 2 diabetes only among men (rs2073162: OR 2.14, p=0.028; rs2073163: OR 2.11, 
p=0.035). 
 
 
The Diabetes Prevention Program 
In the DPP, variants in four genes, including TCF7L2, PPARG2, KCNJ11, and WFS1 have 
been associated with the progression from IGT to type 2 diabetes (Table 4). Similarly with 
the DPS, the association of rs7903146 in TCF7L2 with the risk of developing type 2 
diabetes was stronger in the control group than in the lifestyle intervention group, 
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indicating the possibility of a gene–lifestyle interaction [127]. While the Ala12 allele of the 
Pro12Ala SNP in PPARG2 was associated with a decreased risk of type 2 diabetes in the 
DPP, it was associated with an increased risk in the DPS [114]. In the DPP, the effect was 
also modified by BMI, and a decreased risk was found only among the carriers of the Ala12 
allele with a BMI below 34.5 kg/m
2
 [128]. However, similarly to the Ala12 allele in the 
DPS, the association of the E23K SNP in the KCNJ11 gene with a lower risk of type 2 
diabetes was inverse to the risk-increasing effect of the lysine allele seen in a previous 
meta-analysis [129]. A SNP in the adjacent ABCC8 gene that was in a strong linkage 
disequilibrium with the E23K SNP was also associated with an increased risk of developing 
type 2 diabetes [128]. In the DPS, the E23K SNP was not associated with the progression 
to type 2 diabetes [119], but SNPs in ABCC8 were [119]. It thus remains possible that 
variants in either one or both genes are required to mediate the effects on diabetes risk 
[130]. 
     In the DPP, the results of genome–wide association studies were recently extended to 
evaluate how SNPs in the novel diabetes–associated genes, including exostoses 2 (EXT2), 
CDK5 regulatory subunit associated protein 1-like 1 (CDKAL1), cyclin-dependent kinase 
inhibitor 2B (CDKN2B), insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2), 
hematopoietically expressed homeobox (HHEX), similar to hCG1816027 (LOC387761), 
and solute carrier family 30, member 8 (SLC30A8), affected the incidence of type 2 
diabetes. However, none of the SNPs were statistically significantly associated with the 
incidence of type 2 diabetes [131]. 
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Table 4. Genes and their single nucleotide polymorphisms (SNPs) associated with the risk of developing type 2 
diabetes in the Diabetes Prevention Program (DPP). 
Gene SNP RRtot ptot RRcon pcon RRint pint Reference 
TCF7L2 rs7903146 1.55 <0.001 1.81 0.004 1.15 0.60 [127] 
PPARG2
1
 Pro12Ala 1.24 0.007 1.28 0.17 –
 
–
 
[128] 
KCNJ11
2
 E23K
 
– – 0.71 0.01 1.09 0.61 [130] 
WFS1 rs752854 0.98 0.90 1.14 0.56 0.41 0.056
3 
[132] 
 10012946 0.85 0.026 – – – –  
Abbrevations: –, not reported; DPP, Diabetes Prevention Program; KCNJ11, potassium inwardly rectifying 
channel; NS, non-significant; PPARG2, peroxisome proliferator-activated receptor gamma 2; RR, relative risk;  
SNP, single-nucleotide polymorphism; TCF7L2, transcription factor 7 like 2; WFS1, Wolfram syndrome 1.  
The footnotes tot, con and int refer to the total study population, control group and lifestyle intervention 
group, respectively. Genes are presented in the chronological order of publication. 
1
There was an interaction between genotype and body mass index (p=0.03). Ala12 carriers were more 
susceptible to the deleterious effect of body mass index on diabetes incidence than proline homotsygotes. 
2
The Ala1369Ser SNP in the ABCC8 gene was also studied with essentially identical results to E23K. 
3
The minor homozygotic genotype protected from diabetes among white participants in the intervention 
group (RR=0.30, p=0.048). 
 
Considerations and implications 
The replication of the association of TCF7L2, a relatively powerful genetic factor, with the 
risk of developing type 2 diabetes in both the DPS and the DPP illustrates that large-scale 
lifestyle intervention studies are appropriate for studying genetic variants of high frequency 
and with strong effects on the risk of type 2 diabetes [123,127]. However, these studies 
seem to lack sufficient power to study the associations of variants with a low or modest 
effect on the risk of type 2 diabetes, because even the DPP with more than 3,000 
participants could not replicate the findings of the recent genome-wide association studies 
[131]. In the DPS, a large number of associations of gene polymorphisms with the 
incidence of type 2 diabetes have been reported (Table 3), but it is likely that some of these 
associations are false positives due to the problem of multiple testing [133]. Some of the 
positive associations may, however, be weak and could be confirmed in larger-scale 
genome–wide association studies or in robust meta-analyses of candidate gene studies. 
Nevertheless, in the light of the many previous unreplicated findings in candidate gene 
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studies [134], it is obvious that the number of genetic hypotheses that are tested has to be 
limited to reduce the likelihood of false discovery. 
     The DPS and DPP are, moreover, not directly comparable to the genome-wide 
association studies, and they may also provide complementary evidence on diabetes 
susceptibility genes because of their distinct study design. Whereas the case-control design 
was used in the genome–wide association studies and in most candidate gene studies, the 
DPS and DPP are prospective studies where the participants were at a high risk of type 2 
diabetes at baseline. Therefore, the participants of the DPS and the DPP are likely to have 
been at a relatively late stage in the pathogenesis of diabetes in the beginning of the study. 
The participants of the DPS and DPP were also more homogeneous in characteristics 
(obese with IGT) than type 2 diabetic and their control subjects in case-control studies. This 
may have affected the ascertainment of the role of genetic variation as a risk factor for type 
2 diabetes. The selection of high-risk individuals for a lifestyle intervention study increases 
the number of incident cases, but it may also result in the selection of high-risk genotypes 
that limits the generalisability of the results. Furthermore, half of the participants in the 
DPS and DPP followed a lifestyle intervention, which allowed the investigation of gene-
lifestyle interactions but may have affected the sensitivity of the studies to detect genetic 
main effects. Nevertheless, because of their unique characteristics, intervention studies on 
the prevention of type 2 diabetes may give further insights into the etiology of the disease 
that remain uncovered in case-control studies. 
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PHYSICAL ACTIVITY IN THE PREVENTION OF TYPE 2 
DIABETES 
 
Prospective epidemiological studies 
Prospective epidemiological studies strongly suggest a link between higher levels of 
physical activity and a decreased risk of type 2 diabetes. Individuals with higher levels of 
leisure-time, occupational and commuting physical activity have had 15-60% lower risk of 
type 2 diabetes, and most studies showed a 30-50% reduced risk among physically active 
individuals [135-158]. The benefit has been apparent in both men and women when 
controlled for age, BMI, and several other confounding factors. 
     Cardiorespiratory fitness is considered an objective measure of an individual’s recent 
physical activity pattern [143,159-163]. The studies on cardiorespiratory fitness have 
shown similar results as physical activity studies, but with somewhat stronger magnitude of 
association [143,159-163]. One reason for the stronger association between 
cardiorespiratory fitness and the risk of type 2 diabetes may be that measures of 
cardiorespiratory fitness are more accurate and less prone to misclassification than those of 
physical activity [164]. Physical fitness has a strong genetic background, however, that may 
at least partly be independent of physical activity patterns [165-168]. The same genetic 
factors that are associated with a high level of fitness may also protect from type 2 diabetes 
[168,169]. 
 
Lifestyle intervention studies 
No information on the independent effect of physical activity on the incidence of type 2 
diabetes from randomized controlled trials is available. Five lifestyle intervention studies 
on the prevention of type 2 diabetes, including the Malmö Study from Sweden [109], the 
Da Qing Study from China [110], the Finnish DPS  [111], the DPP in the USA [112], and 
the Indian Diabetes Prevention Study [113] have, however, included physical activity in 
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their intervention programs. Of these, only the Da Qing Study that was randomised by 
clinic rather than by individual, has included an exercise-only intervention arm, whereas the 
four other studies combined physical activity with dietary changes and weight reduction in 
their intervention schemes. In the Da Qing Study, the cumulative incidence of type 2 
diabetes during the 6-year follow-up was similarly low (41%) in the exercise-only group 
compared with the diet-only (44%) and combined diet and exercise (46%) groups [110]. 
The study also suggested that the decrease in the development of type 2 diabetes in the 
exercise-only arm occurred without a substantial change in BMI. However, physical 
activity was poorly documented in the Da Qing Study, and the apparent success of the 
exercise-only intervention may be partly attributable to the significantly higher baseline 
physical activity in the exercise group compared with the control group [110]. 
     Other lifestyle intervention studies have not included an exercise-only arm. However, in 
the DPS, the independent effects of physical activity have been assessed through statistical 
adjustments for the other components of the intervention [170]. The subjects who increased 
their physical activity most (i.e. were in the upper tertile of the change) were 66% less 
likely to develop type 2 diabetes than those in the lower tertile during 4.1 years of follow-
up while adjusting for changes in diet and body weight [170]. In the DPP, there was no 
independent effect of increased physical activity on diabetes risk after adjustment for 
weight change [171]. However, among the participants who did not meet the weight loss 
goal, those who met the activity goal had a 44% reduction in diabetes incidence, 
independent of the small weight loss (-2.9 kg) that occurred [171]. In the Malmö Feasibility 
Study, improved cardiovascular fitness and weight loss were equally correlated with 
improved glucose tolerance [109], a finding that is supported by data from the Study on 
Lifestyle Intervention and Impaired Glucose Tolerance Maastricht [172]. These secondary 
analyses of the data suggest a beneficial effect of physical activity on the risk of type 2 
diabetes. However, evidence from randomised controlled trials with an exercise-only 
intervention arm is required to draw definite conclusions. 
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Mechanisms 
The inverse association between physical activity and the reduced risk of type 2 diabetes in 
epidemiological studies is supported by the evidence of the physiological adaptations that 
take place in response to exercise training. Regular physical activity leads to a number of 
beheficial changes that may improve glycemic control, as summarized in Figure 1 and 
discussed below. 
 
Body composition 
Obesity and particularly excess visceral fat increases insulin resistance and predisposes to 
the development of type 2 diabetes [29,173-180]. Regular physical activity reduces excess 
total and visceral fat and the risk of developing obesity [181-188]. Some randomized 
controlled trials have suggested that exercise training decreases total, visceral, and 
abdominal subcutaneous fat even without weight loss in both normal weight and obese 
individuals [189,190]. Resistance exercise increases skeletal muscle mass, which increases 
muscle glucose uptake [191,192]. Physical activity may thus decrease the risk of type 2 
diabetes by modifying body composition [193]. However, exercise has other beneficial 
effects on glycemic control that are not mediated by body composition [194]. 
 
Muscle insulin signaling 
Skeletal muscle is the major site for insulin-mediated glucose disposal [57], and insulin-
stimulated muscle glucose uptake and utilization are largely impaired in patients with type 
2 diabetes [195-197] and in the first-degree relatives with normal glucose tolerance [196-
198]. Exercise training improves skeletal muscle insulin sensitivity [199,199-204]. The 
mechanisms work likely through increased expression and activity of key proteins involved 
in muscle insulin signaling and glucose metabolism [205,206]. Exercise increases the 
muscle content of glycogen synthase (GS) and glucose transporter isoform 4 (GLUT4) in 
skeletal muscle [207]. The increased content of GS accelerates non-oxidative glucose 
disposal as glycogen [191,199,208]. GLUT4 facilitates the passive diffusion of circulating
   
  
 
   3
2
 
 
 
Figure 1. Mechanisms by which regular physical activity may improve glycemic control and prevent type 2 diabetes. 
Abbreviations: FFA, free fatty acid; GLUT4, glucose transporter 4; GS, glycogen synthase; IL-6, interleukin-6; TNF-alpha, 
tumor necrosis factor-alpha. 
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glucose down its concentration gradient into muscle cells, and muscle glucose transport is 
closely associated with GLUT4 content of the cells [209-211]. However, in type 2 diabetic 
patients, the expression of GLUT4 is similar to insulin-sensitive control subjects [212,213], 
suggesting that other mechanisms are involved in the impairment of insulin sensitivity 
among these individuals. Indeed, some data suggest that exercise may potentiate insulin 
signaling by upregulating the expression and activity of proteins involved in insulin signal 
transduction [206,214,215]. At present, the exact mechanisms are incompletely understood. 
Increased insulin receptor content [191] and autophosphorylation [215], as well as 
increased expression of downstream signaling components of insulin [191,208] have been 
reported. These may contribute to enhancements in insulin signaling in response to regular 
physical activity. 
 
Lipid oxidation capacity 
The exercise-induced increase in the oxidative capacity of skeletal muscle results in a 
higher rate of whole-body fat oxidation at rest and during submaximal exercise [216-218], 
which may prevent lipid-mediated insulin resistance. Intramuscular accumulation of 
triglycerides is modestly associated with insulin resistance in sedentary individuals 
[219,220]. However, athletic skeletal muscle shows high insulin sensitivity despite 
accumulating large amounts of intramyocellular triglycerides [221]. Futhermore, markers 
of skeletal muscle oxidative capacity have proven better correlates of insulin sensitivity 
than muscle lipid content [222]. Indeed, instead of triglycerides themselves, their 
metabolites such as fatty acyl-CoAs, diacylglycerols and ceramides, may induce insulin 
resistance [58-60]. Exercise-induced increase in lipid oxidation capacity improves fatty 
acid turnover and thus prevents the accumulation of fatty acid metabolites in the muscle, 
leading to improvements in insulin sensitivity [223]. 
     The increased oxidation of lipids may also improve liver insulin sensitivity by affecting 
plasma free fatty acid (FFA) levels [50]. Increased FFA supply to the liver may directly 
cause insulin resistance [224]. Exercise decreases the concentration of FFAs in the 
circulation, which may attenuate liver insulin resistance [50,225,226]. 
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Microvascular function 
Insulin is known to control its own, as well as substrate, delivery to muscle by vascular 
effects [65,227]. Insulin increases the number of perfused muscle capillaries, and at the 
same time the total amount of insulin and glucose that enters muscle capillaries. 
Microvascular dysfunction may, however, impair the ability of insulin to increase muscle 
capillary perfusion, and lead to decreased muscle insulin sensitivity [54-56,66,67]. Regular 
physical activity may counteract microvascular dysfunction by increasing the number of 
capillaries surrounding muscle fibers, and by dilating muscle capillaries via increased 
formation of nitric oxide (NO) in the vascular endothelium [227-230]. Increased capillary 
perfusion leads to increased amounts of insulin and glucose seen by the insulin receptor 
[66]. 
 
Anti-inflammatory effects 
Low-grade chronic inflammation, as reflected by increased systemic levels of 
proinflammatory cytokines and C-reactive protein (CRP) [231], may play an important role 
in the pathogenesis of insulin resistance and type 2 diabetes [54-56]. Regular physical 
activity may reduce inflammation by increasing the systemic levels of a number of anti-
inflammatory cytokines [232,233]. In particular, interleukin-6 (IL-6) is produced by muscle 
fibers during exercise, resulting in an exponential (up to 100-fold) increase in circulating 
IL-6 [234-236]. Muscle-derived IL-6 stimulates the appearance of other anti-inflammatory 
cytokines in the circulation, including interleukin-1 receptor antagonist, soluble TNF-α 
receptor, and interleukin-10 [237-240]. IL-6 also inhibits the production of TNF-α, a 
proinflammatory cytokine that is produced by adipose tissue and thought to play a 
mechanistic role in insulin resistance [241-248]. Regular exercise may thus offer protection 
against TNF-α-induced insulin resistance via increased production of IL-6 [236]. Some data 
suggest that exercise also suppresses TNF-α via IL-6 independent pathways [244,249]. 
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Beta-cell function 
Exercise may, at least indirectly, exert beneficial effects on pancreatic β–cell function. 
Chronic exposure of pancreatic islets to elevated levels of glucose and fatty acids impairs 
β–cell function [68-71]. By improving the insulin sensitivity of skeletal muscle, physical 
activity diminishes glycemic stress that may exhaust β–cells. In addition, some data suggest 
that physical activity may directly improve the first-phase insulin secretion, which is an 
indicator of β–cell function [250,251]. 
 
 
GENE–PHYSICAL ACTIVITY INTERACTIONS IN THE 
DEVELOPMENT OF TYPE 2 DIABETES 
 
Regular physical activity exerts beneficial effects on glycemic control. However, 
adaptations to exercise differ substantially between the individuals, and some individuals 
are more responsive to the effects of physical activity interventions than others. For 
example, the magnitude of changes in VO2max, blood pressure, heart rate or HDL 
cholesterol in response to exercise training differs dramatically among individuals [10]. 
Such variability in the responsiveness to physical activity is common for nearly all 
components of health-related fitness [11]. Furthermore, correlations between the exercise-
induced changes in health-related phenotypes are low. In other words, an individual may 
not experience favourable changes in one risk marker, for example, systolic blood pressure, 
in response to physical activity, but may still exhibit highly favourable changes in some 
another trait, such as plasma glucose levels [11]. 
     Three major factors affect phenotype variability: measurement error, environment, and 
genes [252]. Measurement error is small for most phenotype measurements and is usually 
not an important source of variability. Environmental differences, such as history of 
physical activity and diet, are more important but they can, at least partly, be accounted for 
in the research design or through statistical adjustments. After controlling for measurement 
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error and environmental factors, there are still large inter-individual differences in physical 
activity responses that are attributed to genetic variation [10]. Individuals with specific 
genetic profiles are more responsive to physical activity interventions for specific traits, and 
perhaps less responsive or even non–responsive with regard to some other phenotypes [11]. 
Identification of the key genes and alleles that modify the success of physical activity 
interventions is important, as it would increase our understanding of the etiology of type 2 
diabetes and could lead to the development of new therapies. Furthermore, such 
information could be used in the identification of individuals who have the potential to 
benefit most from targeted lifestyle prevention in the prevention of insulin resistance and 
type 2 diabetes [12]. Such predictions would create possibilities for tailoring interventions 
and therapies individually, making them better targeted and more efficient. 
 
Study designs for investigating gene-physical activity interactions  
Several different epidemiological study designs are available to assess gene–physical 
activity interactions, as summarised in Table 5. In addition, genome-wide linkage studies 
have been used to detect such chromosomal loci in which genetic variants modifying 
responses to exercise training could be present (Table 6). 
     Either a short or long–term approach is possible in the study of gene-physical activity 
interactions. Studies with a short follow-up (weeks or months) reflect the immediate 
responses to changes in physical activity, which is important in informing selection of 
individuals for targeted prevention [253]. Studies with a long follow-up gives information 
on gene-physical activity interactions over lifetime. A case-control study may be the best 
design from the lifelong perspective and is efficient in statistical terms, as an equal number 
of cases and controls are recruited. However, since the report of lifestyle habits may be 
biased in individuals who know they have diabetes, recall bias affects the results. 
Furthermore, when investigating traits such as obesity, there is the added problem of 
inference about the direction of causality, as it cannot be determined whether inactivity 
precedes the development of disease, or vice versa [253]. Therefore, prospective studies are 
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also needed to investigate the interactions of genes and physical activity in the development 
of type 2 diabetes.  
 
Table 5. Study designs for the investigation of gene-physical activity interactions 
Study design Use Strengths Weaknesses 
Case-control 
cross-sectional 
Interactions between gene 
variants and physical activity 
on the prevalence of disease 
or levels of related traits 
 
The same number of cases 
and controls are recruited, 
which means efficient 
utilization of subjects. 
Susceptible to recall bias.  
Inference of causality not 
possible. 
Cohort studies  Interactions between gene 
variants and physical activity 
on the incidence of disease 
or changes in levels of 
related traits. 
 
Inference of causality 
possible.  
Less susceptible to recall 
bias. 
Many individuals have to 
be studied but only few 
become informative as 
incident cases, which 
means inefficient 
utilization of subjects.  
Nested case-control 
studies (hybrid 
design). 
 
 
 
 
 
Interaction between gene 
variants and physical activity 
on the incidence of disease 
or changes in levels of 
related traits. 
The same number of cases 
and controls are recruited, 
which means efficient 
utilization of subjects. 
Inference of causality 
possible.  
No recall bias. 
Large cohort study is 
required to have a 
sufficient number of 
incident cases 
Lifestyle intervention, 
secondary analysis 
Interaction between gene 
variants and physical activity 
on the incidence of disease 
or changes in levels of 
related traits. 
Controlled study design.  
Careful follow-up of 
subjects. 
Adjustment for other 
lifestyle changes than 
physical activity required. 
Only a limited number of 
subjects can be included. 
Suitable for common 
variants only. 
Exercise intervention, 
secondary analysis 
The effects of gene variants 
on the responses to exercise 
training. 
 
Exercise-only intervention. 
Controlled study design.  
Careful follow-up of 
subjects. 
Only a limited number of 
subjects can be included. 
Suitable for common 
variants only. 
 
Exercise intervention 
with subjects 
preselected by 
genotype 
 
Tailored intervention in 
preselected genetic groups. 
Confirms whether there is 
differential response to 
physical activity by genotype 
for the outcome of interest. 
Very strong prior 
likelihood of success 
required. 
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The constraints of a case-control study can be removed by nesting the case–control study 
within a cohort, as the recall of exposure then predates the attribution of the disease label, 
and the inference of causality becomes possible [253]. Secondary analyses of lifestyle 
intervention studies are another option. They can only include a limited number of 
participants, which limits statistical power. The focus is on genetic polymorphisms that are 
likely to have only a small influence on the investigated phenotype, and identification of 
true associations thus requires large sample sizes. Power calculations also show that the 
study of interactions between genes and lifestyle requires larger study populations than the 
investigation of genetic main effects [254]. Furthermore, the method used for the 
measurement of physical activity is important, since the precision of this measure is critical 
to the power to detect interactions [15]. Nonetheless, even in a large-scale study with 
precise measurement of lifestyle factors, the number of interactions that are tested has to be 
limited to reduce the likelihood of false discovery. The priority should lie within those 
genes and gene variants that have the greatest biological plausibility for interaction, or that 
are supported by evidence of genetic main effects [253]. 
     Ultimately, if robust evidence on gene-physical activity interactions becomes available, 
a study where individuals are selected on the basis of a risk genotype could be carried out. 
Such a study would be a stepping stone to the introduction of targeted interventions. 
However, the prospect of selecting people by genotype for a trial is presently limited, as 
one would need a very strong prior likelihood of success before carrying out an expensive 
long-term trial that followed people up to a relevant clinical outcome [17]. Therefore, at 
present, the retrospective examination of differential response by genotype in existing 
lifestyle intervention trials is more plausible. 
 
Present evidence on gene-physical activity interactions 
The existing evidence on gene–physical activity interactions in the development of type 2 
diabetes or related metabolic traits consists of genome–wide linkage scans, cross–sectional 
association studies of quantitative traits and relatively small lifestyle intervention studies. 
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Linkage scans 
Two genomic scans have been carried out for intermediate phenotypes of type 2 diabetes in 
the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) Family Study 
[255-257]. These scans have identified loci for the changes in quantitative traits in response 
to a 20-week endurance training program in sedentary healthy individuals, as summarized 
in Table 6. Numerous genes located in these genomic regions may modify the effects of 
endurance training on diabetes–related traits [256,257]. However, the history of linkage 
scans has shown that the scans are not sensitive enough for the detection of variants for 
multigenic diseases, such as type 2 diabetes, where each genetic variant has only a low or 
modest effect on the disease risk [258]. This may be the case with the scans on the exercise-
related chromosomal loci as well, since the effects of exercise are likely mediated by many 
genes, each with only a modest effect on any phenotype of interest [259]. One possibly 
successful example of a linkage scan has, however, been demonstrated in the HERITAGE 
Study. The genomic region 7q31 was first linked to fasting insulin response to exercise 
training [256], and subsequently, two nearby genes, the leptin (LEP) and leptin receptor 
(LEPR), were found to modify the effects of exercise training on glucose homeostasis in a 
candidate gene study [260]. 
 
Table 6. Chromosomal loci associated with responses of intermediate phenotypes of type 2 diabetes to exercise 
training in genome-wide linkage scans. 
Phenotype Subjects Chromosomal loci Reference 
Fasting insulin Caucasians 7q31 [256] 
Insulin sensitivity African-Americans 20q13, 22q11-12 [257] 
Acute insulin response African-Americans 15q15, 18q12 [257] 
Disposition index Caucasians 1p35, 3q25, 6p21-22, 7q21, 1p13, 12q24 [257] 
Disposition index African-Americans 6p22, 13q14 [257] 
Glucose effectiveness African-Americans 1p31, 1q44, 2p22-21, 10p12, 10q23, 12q13, 
15q26, 19q13 
[257] 
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Candidate gene studies 
In candidate gene association studies, several genes have shown an interaction with 
physical activity on phenotypes of glucose and insulin metabolism or adiposity (Table 7).
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Thus far, two main study designs have been utilised to investigate interactions between 
physical activity and genes in candidate gene studies (Table 7). Firstly, observational 
analyses have been carried out on the interaction between the habitual level of physical 
activity and genetic polymorphisms. Secondly, exercise intervention studies have been 
conducted to compare responses to exercise training among candidate gene genotypes. 
Most of the detected interactions between genes and physical activity have not been 
replicated. At present, the ADRB2 gene; the fat mass and obesity associated gene 
(FTO); the guanine nucleotide binding protein, beta polypeptide 3 gene (GNB3); and the 
PPARG2 gene are the only genes that have interacted with physical activity on body 
weight or glucose and insulin metabolism phenotypes in more than one study (Table 7). 
     The ADRB2 gene encodes a receptor that binds the endogenous catecholamines 
epinephrine and norepinephrine, which are released during sympathetic nervous system 
activity causing increased lipolysis. Physical activity stimulates the sympathetic nervous 
system [284]. Variation in the ADRB2 gene could modify the exercise-induced 
activation of lipolysis via sympathetic nervous system and thereby affect the magnitude 
of weight changes in response to physical activity. Some reports suggest that fat 
oxidation rate [285,286] and lipolysis [285] are decreased in Glu27Glu obese women 
compared with Gln27Gln homozygous individuals after a bout of exercise. 
     Three studies have detected an association between an SNP in the ADRB2 gene and 
physical activity on body weight. In a cross-sectional study among 836 French men and 
women, body weight, waist circumference, and waist-to-hip ratio were higher in 
physically inactive men who carried the Glu27 allele of the Glu27Gln SNP in ADRB2 
than in inactive men with other genotypes, whereas no significant difference between 
the genotypes was found among men who were physically active [262]. No significant 
difference between the genotypes was, however, found among women [262]. In 
contrast, a case-control study among 139 obese Spanish women and their 113 healthy 
controls found that the carriers of the Glu27 allele who were active in their leisure-time, 
had a higher BMI than other individuals with the same level of activity, whereas no 
difference between the genotypes was seen among the inactive individuals [263]. In the 
third report on ADRB2 and physical activity, the responses of ADRB2 genotypes to a 
20-week endurance training program were followed among 482 white and 260 black 
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participants [264]. BMI, fat mass, and percent body fat decreased more during the 
endurance training program in white women who were homozygous for the Gly16 allele 
of the Arg16Gly SNP in ADRB2 than in white women with other genotypes [264]. 
However, no difference in the responses to the training program were found among the 
genotypes of the Glu27Gln SNP. The findings on variation in the ADRB2 gene and 
changes in body weight in response to physical activity are thus inconsistent with regard 
to the specific variants that have modified the responses, as well as with regard to the 
effect of gender. 
     Very recently, four studies have suggested an interaction between SNPs in the FTO 
gene and physical activity. Firstly, the carriers of the rare homozygous genotype of 
rs9939609 in FTO had a higher BMI than the common homozygous individuals among 
5,554 Danish men and women, but the difference was only seen in the individuals who 
were physically inactive [268]. Secondly, the rare alleles of rs1861868 and rs1477196 
in FTO were associated with BMI only among those with low physical activity scores 
among 702 Amish individuals [269]. Thirdly, among 4,672 Finnish adolescents, the 
association of the rare allele of rs1421085 in FTO with BMI was strongest in the 
individuals who were physically inactive [270], and fourthly, the rare allele of the same 
rs1421085 SNPs was associated with higher BMI among physically inactive 
individuals, but not in those who were physically active among 3,167 French men and 
women [270]. Although the findings on the interaction between the FTO gene and 
physical activity are fairly consistent, a recent study among 4,210 individuals from the 
Singapore National Health Survey did not find an association between the FTO gene 
and physical activity on BMI [287]. Furthermore, the mechanism that would mediate 
the interaction between the FTO gene and physical activity on adiposity remains 
unresolved. 
     Two studies have indicated that the C-825T variant in the GNB3 gene may modify 
the association between physical activity and fat mass. In the HERITAGE Study, 
changes in fat mass and body fat percentage differed significantly among 255 black men 
and women on the completion of the 20-week endurance training program [271]. The 
TT homozygotic individuals had the largest decrease in fat mass and fat percentage 
while the CC homozygotes showed little or no decrease. Consistently, in a recent cross-
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sectional study among 3,378 men and women, each T allele was associated with a 20% 
reduced prevalence of obesity in physically active individuals, whereas each T allele 
was associated with a 23% decreased prevalence in low-active individuals [272]. 
Physical activity may thus be more effective in reducing obesity among the T allele 
carriers of the C-825T SNP. It has been suggested that by influencing G protein 
receptor–mediated signal transduction, variation in the GNB3 gene may negatively 
affect the interaction of catecholamines with β-adrenergic receptors during physical 
activity [288]. This could lead to a decrease in response to catecholamines, and 
consequently, to altered energy utilization and adipose homeostasis [289]. 
     The PPARG2 gene encodes PPARγ, a member of the peroxisome proliferator-
activated receptor subfamily of nuclear receptors, which regulates the transcription of a 
number of genes involved in adipocyte differentiation [290-293] and insulin 
sensitization [294]. Thiazolidinediones, the insulin-sensitizing drugs used in the 
treatment of type 2 diabetes, target PPARG [294]. The most widely studied SNP of 
PPARG2, the Pro12Ala, has been associated with an increased insulin sensitivity and a 
moderately decreased risk of type 2 diabetes in various populations [295]. Moreover, 
many studies suggest that physical activity modifies the association of the Pro12Ala 
SNP with glucose homeostasis and the risk of type 2 diabetes [278-282,296-299]. 
     A statistically significant difference between the Pro12Ala genotypes in insulin 
sensitivity improvement in response to exercise training has been reported in three 
different studies (Table 7). Firstly, the Ala12 carriers of the Pro12Ala SNP had a larger 
decrease in fasting plasma glucose in response to endurance or resistance training in 139 
patients with type 2 diabetes [280]. Secondly, the Ala12 allele was associated with an 
improvement in insulin sensitivity after exercise training in 123 healthy Japanese men 
[278]. Thirdly, endurance training resulted in a greater improvement in insulin area 
under the curve during an oral glucose tolerance test in the Ala12 allele carriers among 
32 sedentary men [279]. Furthermore, in a study among 29 normoglycaemic first-degree 
relatives of type 2 diabetic patients, insulin sensitivity tended to improve more in Ala12 
carriers than in Pro12 homozygotes [281]. Physical activity may thus be more effective 
in improving insulin sensitivity in carriers of the Ala12 allele than among others. In a 
recent cross-sectional study among 236 non-Hispanic whites from Colorado, however, 
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the Ala12 allele was associated with a lower risk of type 2 diabetes among the 
individuals with a lower level of physical activity, whereas no difference between the 
genotypes was found among those with a higher level of  physical activity [282]. It thus 
remains unclear whether the exercise-induced improvements in insulin sensitivity 
among the Ala12 carriers translate to benefits in the prevention of type 2 diabetes. 
     Overall, the present evidence concerning the details of gene-physical activity 
interactions in the development of type 2 diabetes is weak. The cross-sectional 
observational studies and various intervention studies have mostly included only small 
numbers of participants. No nested case-control studies (hybrid design) on the 
interaction between genes and physical activity have yet been performed. So far, only 
one cross-sectional study [282] and no prospective studies have looked at an interaction 
between a genetic variant and physical activity on the risk of type 2 diabetes. Moreover, 
as most of the detected interactions have not been replicated, there is a strong possibility 
that they represent false positive findings.  
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III AIMS OF THE STUDY 
 
The main aim of the study was to detect gene variants that contribute to individual 
differences in the magnitude of the effects of physical activity on the incidence of type 2 
diabetes in the Finnish DPS. 
 
The following sub-themes were covered: 
 
1. The associations of SNPs in the PPARG2 gene with the incidence of type 2 
diabetes and their interactions with physical activity (Study I). 
 
2. The interactions of SNPs in the SLC2A2, ABCC8, and KCNJ11 genes with 
physical activity on the incidence of type 2 diabetes (Study II). 
 
3. The interactions of SNPs in the ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, 
and GHRL genes with physical activity on the incidence of type 2 diabetes and on 
the changes in characteristics of the metabolic syndrome (Study III). 
 
4. The interactions of SNPs in the TNF and IL6 genes with physical activity on the 
changes in serum levels of CRP and IL-6 (Study IV). 
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IV METHODS 
 
STUDY POPULATION AND DESIGN 
 
The DPS is a randomized controlled trial with the main aim to investigate the effects of 
intensive lifestyle counselling on the incidence of type 2 diabetes in high-risk 
(overweight, glucose intolerant) individuals. Altogether 522 subjects (172 men, 350 
women) aged 40–64 years were recruited, and were randomized into the intervention 
group (n = 265) or the control group (n = 257) [111,300].  
     The main goals of the lifestyle intervention were selected on the basis of knowledge 
on the major risk factors for type 2 diabetes [173,301-303]. The following goals were 
chosen: moderate-to-vigorous exercise ≥30 minutes per day, ≥5% reduction in body 
weight, intake of total fat ≤30% and saturated fat ≤10% of daily energy consumed, and 
intake of dietary fiber ≥15 grams per 1000 kilocalories of energy intake [300,304]. To 
reach the lifestyle goals, the participants in the intervention group received 
individualized lifestyle counseling via face-to-face consultation sessions with the study 
nutritionist. The sessions were organized seven times during the first year, and every 
three months thereafter. The goal was to look for individual ways for each participant to 
reduce weight, improve dietary habits and increase physical activity and, importantly, to 
equip the participants with the necessary knowledge and skills to achieve gradual but 
permanent behavioural changes [304]. 
     In the counseling sessions, the dietary advice was based on 3-day food records which 
were completed four times yearly [304]. The level of physical activity was followed 
through annual physical activity questionnaires. Participants were encouraged to 
increase endurance exercise, such as walking, jogging, swimming, aerobic ball games, 
and skiing. Lifestyle physical activity was also promoted. In three of five centers 
supervised, progressive, individually tailored circuit-type resistance training was also 
offered to the participants of the intervention group free of charge. 
     The participants of the control group received general oral and written information 
about diet and exercise at baseline. The message to reduce weight, increase physical 
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activity, and make healthy changes in diet was the same as for the participants in the 
intervention group, but no specific individualised programs were offered [304]. 
 
ASSESSMENTS 
 
Assessment of physical activity 
Physical activity was quantified at baseline and during yearly follow-up visits by the 
Kuopio Ischemic Heart Disease Risk Factor Study (KIHD) 12-Month Leisure-Time 
Physical Activity Questionnaire (Appendix I) [305]. The questionnaire is designed to 
give detailed information on the most common conditioning and lifestyle leisure-time 
physical activities among middle-aged Finnish men. The duration, frequency and mean 
intensity of leisure-time physical activity are logged into the questionnaire as recalled 
over the previous year. Throughout the follow-up, 89-98% of those remaining in the 
study completed the forms [306]. 
     The original physical activity estimates were adjusted by reducing the MET values 
assigned to different subjective intensities for given forms of physical activity by 30%. 
The adjustment was based on a bicycle exercise test among a sample of DPS 
participants where maximal oxygen uptake was on average ~30% lower than in the 
younger and leaner men who participated in the population-based KIHD cohort study 
[305]. 
     For the physical activity analyses of the DPS, the average duration (minutes per 
week) of total leisure–time physical activity, moderate-to-vigorous physical activity, 
and low–intensity physical activity were calculated. Moderate-to-vigorous physical 
activity was defined as ≥3.5 METs, and low-intensity physical activity as <3.5 METs (1 
MET is defined as metabolic expenditure at rest, corresponding to an oxygen uptake of 
3.5 ml O2/kg). The usual moderate-to-vigorous physical activities included moderate-to-
high intensity walking, bicycling, swimming, resistance training, cross-country skiing, 
jogging, ball games, and lifestyle activities, such as chopping wood or clearing brush 
[306]. The common low-intensity activities included low-intensity walking or bicycling, 
yard work and gardening, and picking berries and mushrooms. 
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Assessment of diet 
All study participants were asked to complete a 3-day food record at baseline and before 
every annual visit [304]. The nutrient intakes were calculated using a dietary analysis 
programme and database developed in the National Public Health Institute [307]. Due to 
the time-consuming and therefore costly dietary data management, only the data from 
baseline and years 1, 2, and 3 of the intervention period were included into the final 
database [307]. 
 
Assessment of overweight and obesity 
Body weight and height were measured annually, and BMI was calculated as weight 
divided by height squared (kg/m
2
). Waist circumference was measured midway between 
the lowest rib and iliac crest and hip circumference over the great trochanters, with 0.5 
cm precision while the subject was standing. Overweight was defined as BMI 25.0-29.9 
kg/m
2
 and obesity was defined as BMI ≥30 kg/m2 [300]. 
 
Assessment of glucose homeostasis and type 2 diabetes 
Glucose homeostasis was assessed by 2-hour oral glucose tolerance tests (OGTT) 
annually in all subjects. The subjects were asked to fast and to refrain from strenuous 
exercise for 12 hours before the OGTT. Diabetes was defined according to the 1985 
criteria of the World
 
Health Organization as either a fasting plasma glucose 
concentration ≥7.8 mmol/l or a plasma glucose concentration ≥11.1 mmol/l two hours 
after a 75-g oral glucose challenge in an OGTT [308]. If type 2 diabetes was diagnosed 
in the first OGTT, a second OGTT was performed to confirm the diagnosis [300]. 
Plasma glucose levels were measured by the glucose oxidase method (Daiichi, Kyoto, 
Japan). 
 
Other assessments 
Blood pressure was measured twice from the right arm using a standard 
sphygmomanometer after 10 minutes of rest with the subject sitting. The mean of the 
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two measurements was used in the calculations. Serum insulin concentrations were 
measured with the two-site monoclonal antibody radioimmunoassay method (Pharmacia 
Diagnostica, Uppsala, Sweden). Serum concentrations of total cholesterol, high-density 
lipoprotein (HDL) cholesterol and triglycerides were measured by an enzymatic assay 
(Boehringer Mannheim, Mannheim, Germany). Serum concentration of high-sensitivity 
CRP (hs-CRP) was assessed by an immunonephelometric assay (Dade Behring, 
Marburg, Germany). Serum interleukin-6 (IL-6) was assessed by an enzyme-linked 
immunosorbant assay (ELISA) using recombinant IL-6 and an antibody pair from 
Sanquin (Amsterdam, the Netherlands) [309]. 
 
Genotyping 
The genotyping for the SNPs rs3856806 (His477His) in PPARG2, and –174C/G 
(rs1800795) in IL6 was performed in 490 subjects by the PCR–SSCP (single–strand 
conformation polymorphism) method [115,310]. The SNPs in the LEPR and GHRL 
genes were genotyped for 507 subjects, and the SNPs in the ADRB2, ADRB3, TNF, 
IGF1R, and LIPC genes for 490 subjects by the RFLP (restriction fragment length 
polymorphism) method [115-117,120,122,124,311]. The rs1801282 in PPARG2 was 
genotyped by the PCR–SSCP method for 490 subjects [310], and with the TaqMan 
Allelic Discrimination Assays (Applied Biosystems, Foster City, California, USA) for 
17 subjects. All other SNPs in PPARG2, and the SNPs in TCF7L2 [123] were 
genotyped for 507 subjects using the TaqMan assays. 
 
Statistical methods 
The SPSS-software (Chicago, IL) was used for all statistical analyses. Haplotypes were 
reconstructed with SNPHAP, version 1.3 [312], which estimates haplotype frequencies 
using the expectation-maximization algorithm [313]. The genetic analyses were 
performed using either the dominant or the additive model. The dominant model was 
preferred in most cases because the number of individuals carrying the rare homozygous 
genotype was small. 
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     Baseline differences in continuous variables among the genotypes were evaluated by 
the univariate ANOVA, general linear model. Logarithmic and square root 
transformations were used to transform variables that were not normally distributed to 
approximate normality before further statistical analyses. When the variance and 
normality assumptions were not met, the non-parametric Mann-Whitney U test or 
Kruskal-Wallis test was used. Baseline differences in categorical variables among the 
genotypes, and the deviations of genotype frequencies from the Hardy-Weinberg 
equilibrium were tested with the chi square test. 
     Cox regression analysis was used to assess whether the SNPs and haplotypes were 
associated with the progression from IGT to type 2 diabetes. Cox regression was also 
used to analyse the interactions of the SNPs and haplotypes with the lifestyle 
intervention, physical activity, or anthropometric characteristics on the progression from 
IGT to type 2 diabetes during the follow-up. The univariate ANOVA, general linear 
model, was used to assess interactions between physical activity and SNPs on 
characteristics of the metabolic syndrome or on the serum levels of hs-CRP and IL-6. 
     The original DPS ended after an average follow-up of 3.2 years when a total of 86 
incident cases of type 2 diabetes were diagnosed [111]. The associations of SNPs with 
the risk of type 2 diabetes have therefore been analyzed using the first 3 years of the 
follow-up only. To increase statistical power for detecting interactions on the risk of 
type 2 diabetes, follow-up was extended by one year (average follow-up 4.1 years). 
During the 4.1-year follow-up, 116 of the 522 participants of the DPS developed type 2 
diabetes. Of all the 522 subjects, 487 completed physical activity questionnaires at 
baseline and at least once during the intervention so that the average changes in physical 
activity could be calculated.  These subjects were included in the present analyses on 
the interactions of SNPs with changes in physical activity. (Table 8). Of the 487 
subjects, 107 developed type 2 diabetes during the follow-up. 
     The 1-year follow-up time was used in the analyses of interactions between 
polymorphisms and physical activity on the changes in characteristics of metabolic 
syndrome in Study III, as well on the changes in concentrations of serum hs-CRP and 
IL-6 in Study IV (Table 8). Only the 469 subjects who had 1-year data on physical 
activity available were included in these analyses. Of these individuals, 390 had 1-year 
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data on serum hs-CRP and IL-6, and thus only these subjects were included in Study IV 
(Table 8). In Study IV we also excluded all the 25 individuals who had hs-CRP levels 
>10 mg/L at baseline or at the 1-year examination to avoid the impact of acute 
infections or other proinflammatory conditions on the results. Furthermore, as it was 
previously found that regular exercise reduced hs-CRP levels only among individuals 
with high (≥3 mg/L) baseline levels of hs-CRP [314], the interactions between the 
polymorphisms and lifestyle changes on hs-CRP levels were analysed separately among 
those with high (≥3 mg/L) or lower (<3 mg/L) baseline levels of hs-CRP. 
     The changes in physical activity during the total length of the intervention were 
calculated by subtracting the baseline physical activity values (in hours per week) from 
averaged annual physical activity values. The changes in physical activity during the 
first year of the follow-up were calculated by subtracting the baseline physical activity 
values from the first-year physical activity values. Changes in anthropometric, dietary, 
and biochemical measures were calculated similarly, but the dietary intakes were 
available from the first 3 years of the follow-up only [307]. The intakes of total and 
saturated fat and fiber were adjusted by daily energy intake with linear regression 
analysis before further statistical analyses [306]. 
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Table 8. Sample sizes, follow-up times, and studied genes, PA variables and outcomes in Studies I-IV. 
Study N Genes PA variables
1
 Outcomes Follow-up times 
Study I 487 PPARG Total PA Incidence of type 2 diabetes. Average 4.1 years. 
Study II 487 SLC2A2 
ABCC8 
KCNJ11 
Total PA 
Moderate-to-
vigorous PA 
Incidence of type 2 diabetes. 
Changes in fasting and 2-hour 
glucose.  
Average 4.1 years. 
Study III 487 ADRB2 
ADRB3 
TNF 
IL6 
IGF1R 
LIPC 
LEPR 
GHRL 
Total PA 
Moderate-to-
vigorous PA 
Incidence of type 2 diabetes. 
Changes in body mass index, 
waist circumference, systolic 
blood pressure, HDL cholesterol 
and triglycerides. 
Average 4.1 years for the 
incidence of type 2 diabetes. 
1 year for changes in 
continuous traits. 
Study IV 390 IL6 
TNF 
Moderate-to-
vigorous PA 
Changes in serum interleukin-6 
and C-reactive protein. 
1 year. 
Abbreviations: ABCC8, ATP-binding cassette, sub-family C (CTFR/MRP), member 8; ADRB2, adrenergic receptor beta-
2; ADRB3, adrenergic receptor beta-3; GHRL, ghrelin/obestatin prepropeptide; HDL, high-density lipoprotein; IGF1R, 
insulin-like growth factor 1 receptor; IL6, interleukin 6; KCNJ11, potassium inwardly rectifying channel; LEPR, leptin 
receptor; LIPC, hepatic lipase; PA, physical activity; PPARG2, peroxisome proliferator-activated receptor gamma 2; 
SLC2A2, solute carrier family 2 (facilitated glucose transporter), member 2; TNF, tumor necrosis factor.  
1
PA was measured in hours per week. Total PA refers to the total amount of PA and moderate-to-vigorous PA to the 
amount of moderate-to-vigorous intensity PA (a subcategory of total PA). 
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V RESULTS 
 
The PPARG gene (Study I) 
 
Seven SNPs in the PPARG gene were genotyped. Two of them, the rs1801282 and 
rs3856806 SNPs, were selected because of their associations with insulin resistance and 
type 2 diabetes in other studies [315]. The five other SNPs were chosen from the 
HapMap data [316], and from the study investigating the association of SNPs in 
PPARG with the response to troglitazone [317]. To investigate the effects of SNP 
combinations on the risk of type 2 diabetes, we reconstructed haplotypes of the seven 
SNPs. 
     Altogether the rs17036314, rs1801282 (Pro12Ala), rs4135263, rs2972162, 
rs2938395, and rs3856806 (His477His) SNPs covered 74% (with r
2
 ≥0.8 and MAF 
≥5%) of the variation in the PPARG gene in the HapMap CEU (Utah residents with 
ancestry from northern and western Europe, NCBI build 35). In addition, the rs1152003 
SNP covered the 3’ flanking region of PPARG. The schematic locations of the SNPs 
along the PPARG gene are presented in Figure 2. 
 
 
Figure 2. Positions of the SNPs in the PPARG gene. Exons are marked by black (coding 
region) or white (untranslated region) boxes. The coding region of the PPARγ1 is 
contained in the exons 1 to 6. The coding region of the PPARγ2 is contained in the 
exons B, and 1 to 6. Exons A1 and A2 encode the untranslated region of the PPARγ. 
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Baseline differences in fasting glucose 
The carriers of the rare allele of rs17036314, rs1801282 (Pro12Ala), or rs3856806 
(His477His), and the carriers of the common homozygous genotype of rs1152003, had 
higher fasting plasma glucose concentrations than subjects with the other genotypes (p 
= 0.029, p = 0.016, p = 0.004 or p = 0.035, respectively, adjusting for age, gender and 
BMI). Similarly, the carriers of the haplotype CGTCATC that contains the rare alleles 
of rs17036314, rs1801282 and rs3856806, and the common allele of rs1152003, had an 
increased fasting glucose compared with the non-carriers (p = 0.017).  
 
Associations with the risk of type 2 diabetes 
The rare alleles of rs17036314 and rs1801282 (Pro12Ala) were associated with the risk 
of type 2 diabetes in the DPS, but after the adjustment for the baseline fasting glucose, 
the association was significant only for rs17036314 (Figure 3) (p = 0.037 for rs1801282 
without the adjustment for fasting glucose). The CGTCATC haplotype, containing the 
risk alleles of rs17036314 and rs1801282, had a stronger association with the risk of 
type 2 diabetes than the individual SNPs before adjustment for baseline fasting glucose 
(p = 0.022), but not after (p = 0.088). 
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Figure 3. Relative risk (±95% CI) of progressing from impaired glucose tolerance to type 2 diabetes among 
genotypes (rare allele vs. common homozygous genotype) of SNPs in the PPARG gene. The values are 
adjusted for age, gender, intervention, fasting glucose and weight at baseline, as well as weight change 
during follow-up. 
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Although rs1152003 in the 3' flanking region of PPARG was not directly associated 
with the risk of type 2 diabetes, it had a significant interaction with the lifestyle 
intervention and tended to increase the risk of type 2 diabetes in the intervention group 
(Figure 4). Adjustment for rs1801282 (Pro12Ala) genotype did not affect the 
associations. 
 
 
Figure 4. New cases of type 2 diabetes in the intervention and 
control groups according to genotypes of rs1152003 in PPARG. 
Percentages show the proportion of genotype carriers who 
progressed to type 2 diabetes. Relative risk for G-allele carriers 
was 1.9-fold (95% CI 1.0-3.6; p=0.05) in the intervention group 
and 0.8-fold (95% CI 0.5-1.3; p=0.29) in the control group, 
adjusting for age, gender, fasting glucose and weight at 
baseline, and weight change. p=0.027 for the adjusted 
interaction between group and rs1152003 genotype. 
  
Interactions with physical activity 
Apart from their direct associations with type 2 diabetes, rs17036314 and rs1801282 
(Pro12Ala) interacted with changes in the total amount of physical activity, categorized 
by median (0.6 h/wk), on the risk of type 2 diabetes during the follow-up (Figure 5). 
The risk alleles were associated with type 2 diabetes only in the lower half of the change 
in physical activity, whereas no association was seen in the upper half. 
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Figure 5. New cases of type 2 diabetes among genotypes of the rs17036314 and rs1801282 SNPs in 
PPARG according to the change in physical activity (PA) during 4.1-years of follow-up. Relative risks for 
rare allele carriers were 2.5-fold (95% CI 1.4-4.4) and 0.6-fold (95% CI 0.3-1.2) for rs17036314, and 2.2-
fold (95% CI 1.3-3.7) and 0.7-fold (95% CI 0.3-1.4) for rs1801282 in the upper and lower half of the 
change in physical activity, respectively, adjusting for age, gender, intervention, weight, dietary risk 
factors, baseline physical activity, and baseline fasting glucose. p = 0.002 and p = 0.031 for the 
adjusted interaction between the change in physical activity and rs17036314 or rs1801282 genotype, 
respectively. 
 
 
The SLC2A2, ABCC8, and KCNJ11 genes (Study II) 
 
Four SNPs from both the SLC2A2 (rs5393, rs5394, rs5400, and rs5404) and the ABCC8 
(rs3758947, rs2188966, rs3758953, and rs1799859) genes, and one SNP (rs5219) from 
the KCNJ11 gene were investigated. However, as the genotype distribution of ABCC8 
rs2188966 deviated from the Hardy-Weinberg equilibrium (p < 0.001), it was excluded 
from all further analyses. The schematic positions of the SNPs in SLC2A2 and ABCC8 
are presented in Figure 6. The E23K SNP (rs5219) was located in exon 1 of KCNJ11. 
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Figure 6. Positions of the SNPs in the SLC2A2 (upper) and ABCC8 (lower) 
genes. Exons are marked with white boxes. 
 
In addition to the individual SNPs, we reconstructed haplotypes based on the four SNPs 
in SLC2A2 that were in close linkage disequilibrium with each other (r
2
>0.6 between 
each pair of SNPs). Seven haplotypes (reconstructed of rs5393, rs5394, rs5400, and 
rs5404) were found: ACCG, CTTA, ACTG, CCTG, CCTA, CTTG, and ACTA.  
 
Interactions with physical activity 
A significant interaction with the change in moderate-to-vigorous physical activity on 
the risk of type 2 diabetes was found for rs5393, rs5394, and rs5404 in SLC2A2 (p = 
0.027, p = 0.022, and p = 0.022 for the interaction, respectively, adjusting for age, 
gender, intervention, body weight and diet). Similarly, the CTTA haplotype that 
contained the rare alleles of all four genotyped SNPs had an interaction with physical 
activity (p = 0.021) (Figure 7). Those who did not carry the CTTA haplotype tended to 
have a higher risk of type 2 diabetes than the CTTA carriers in the lower tertile of the 
change in physical activity, but tended to have a lower risk in the upper tertile. 
Consistently, there was an interaction between the CTTA haplotype and moderate-to-
vigorous physical activity on the change in 2-h plasma glucose during the follow-up 
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(Figure 8). Those who did not carry the CTTA haplotype had an increase in 2-h glucose 
levels compared to the CTTA carriers in the lower tertile of physical activity, whereas 
no significant difference between genotypes was seen in the upper tertile. 
 
 
Figure 7. New cases of type 2 diabetes among carriers and non-carriers of SLC2A2 CTTA haplotype or A-
allele of ABCC8 rs3758947 SNP in tertiles of change in moderate-to-vigorous physical activity during 4.1-
years of follow-up. Relative risks in the upper, middle, and lower tertile of physical activity were 2.2-fold 
(95% CI 0.9-5.2), 1.6-fold (95% CI 0.7-3.5) and 0.4-fold (95% CI 0.1-1.3) for non-carriers of CTTA, and 5.6-
fold (95% CI 2.5-1.3), 1.0-fold (95% CI 0.5-1.8) and 1.2-fold (95% CI 0.4-3.7) for non-carriers of A-allele of 
rs3758947, respectively, adjusting for age, gender, intervention, weight, and dietary risk factors. p = 
0.021 and p = 0.007 for the adjusted interaction between change in moderate-to-vigorous physical 
activity and the carrier status of SLC2A2 CTTA or rs3758947 A-allele, respectively. 
 
Similarly with the CTTA haplotype of SLC2A2, rs3758947 of ABCC8 interacted with 
moderate-to-vigorous physical activity on the conversion to type 2 diabetes (p = 0.007, 
adjusting for age, gender, intervention, weight and diet) (Figure 7). The carriers of the 
common homozygous genotype of rs3758947 had an increased risk of type 2 diabetes in 
the lower tertile of the change in moderate-to-vigorous physical activity, whereas no 
statistical difference between the genotypes was seen in the middle or upper tertiles. 
Consistently, the rs3758947 also interacted with physical activity on the change in 2-
hour plasma glucose (Figure 8). Those who carried the common homozygous genotype 
had an increase in 2-h glucose levels compared to rare allele carriers in the lower tertile 
of physical activity, whereas no significant difference between genotypes was seen in 
the middle or upper tertiles. 
 
 62 
 
 
SLC2A2  CTTA haplotype
-1,00
-0,50
0,00
0,50
1,00
1,50
2,00
lower tertile middle tertile upper tertile
C
h
an
ge
 in
 2
-h
 p
la
sm
a 
gl
u
co
se
 (
m
m
o
l/
l)
ABCC8 rs3758947 (G/A)
-1,00
-0,50
0,00
0,50
1,00
1,50
2,00
lower tertile middle tertile upper tertile
C
h
an
ge
 in
 2
-h
 p
la
sm
a 
gl
u
co
se
 (
m
m
o
l/
l)
 
Figure 8. Difference (± 95% CI) in the change in 2-h plasma glucose between non-carriers vs. carriers of 
SCL2A2 CTTA haplotype and between non-carriers vs. carriers of A-allele of ABCC8 rs3758947 SNP in 
tertiles of change in moderate-to-vigorous physical activity during 4.1-years of follow-up. The values are 
adjusted for age, gender, intervention, weight, dietary risk factors, and baseline 2-h glucose. p = 0.022 
and p = 0.015 for the adjusted interaction between change in moderate-to-vigorous physical activity and 
the carrier status of the CTTA haplotype or the rs3758947 A-allele, respectively. 
 
No interaction with physical activity was found for the E23K SNP (rs5219) in KCNJ11 
(data not shown). 
 
 
The ADRB2, ADRB3, IGF1R, LIPC, LEPR, GHRL, and TCF7L2 
genes (Study III) 
 
One SNP from each of the ADRB2, ADRB3, IGF1R, and LIPC genes, three SNPs of the 
LEPR gene, six SNPs of the GHRL gene, and two SNPs of the TCF7L2 gene were 
investigated [92-94,97,99-101]. The genotypes of the SNPs in ADRB2, ADRB3, IGF1R, 
and LIPC were available for 490 subjects, and the genotypes of the SNPs in LEPR, 
GHRL, and TCF7L2 were available for 507 subjects. 
 
Baseline differences in physical activity 
The baseline level of total physical activity differed among two SNPs in GHRL. The 
level of physical activity was higher in the carriers of the Met allele of rs696217 
 63 
 
 
(Leu72Met) and in the carriers of the A allele of rs26802 (–501A/C) in GHRL than in 
those carrying the common homozygous genotypes (p = 0.032 and p = 0.034, 
respectively). 
  
Interactions with physical activity 
There were no significant interactions between the SNPs in the ADRB2, ADRB3, 
IGF1R, LIPC, LEPR, GHRL, or TCF7L2 genes and the change in total or moderate-to-
vigorous physical activity on the risk of type 2 diabetes. However, interactions of SNPs 
in LEPR and GHRL with physical activity on changes in some characteristics of the 
metabolic syndrome were found. 
     Rs696217 (Leu72Met) in GHRL modified the effect of moderate–to–vigorous 
physical activity on changes in BMI and waist circumference during the first year of the 
intervention of the DPS (p = 0.001 and p = 0.006 for the interaction on BMI and waist 
circumference, respectively) (Figure 9). BMI and waist circumference decreased more 
with increasing tertiles of physical activity in the carriers of the Met allele than among 
the carriers of the common homozygous genotype. 
 
 
Figure 9. 1-year changes (mean and standard error of mean) in body weight and waist circumference 
among the genotypes of GHRL rs696217 (Leu72Met) SNP in tertiles of change in moderate-to-vigorous 
physical activity. p-values are for the linear trend. The values are adjusted for age, gender, intervention, 
energy intake, and the baseline values of the dependent variable and physical activity. p = 0.001, and p = 
0.006 for the adjusted interactions on body weight and waist circumference, respectively. 
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Rs26802 (–501A/C) in GHRL interacted with the change in total physical activity on the 
change in serum HDL cholesterol concentrations (p = 0.005 for the interaction) (Figure 
10). The HDL cholesterol concentration increased in the middle and upper tertiles of 
physical activity among the carriers of the common homozygous genotype, but no 
increase in HDL cholesterol was seen in the carriers of the C allele. 
     Rs1137100 (Lys109Arg) in LEPR modified the effect of change in total physical 
activity on change in systolic blood pressure (p = 0.017) (Figure 10). Systolic blood 
pressure decreased only in individuals with the Lys109Lys genotype who increased 
their physical activity, whereas the carriers of the Arg109 allele seemed unresponsive to 
changes in physical activity. 
 
 
Figure 10. 1-year changes (mean and standard error of mean) in high-density lipoprotein (HDL) 
cholesterol or systolic blood pressure among the genotypes of GHRL rs26802 or LEPR rs1137100 
(Lys109Arg) SNP, respectively, in tertiles of change in total physical activity. p-values are for the linear 
trend. The values are adjusted for age, gender, intervention, body mass index, and the baseline values of 
the dependent variable and physical activity. The rs26802 was additionally adjusted for fat intake. p = 
0.005, or p = 0.017 for the adjusted interaction between physical activity and GHRL rs26802 or LEPR 
rs1137100 SNP, respectively. 
 
 
The TNF and IL6 genes (Studies III & IV) 
 
Rs1800629 (G-308A) in TNF and rs1800795 (C-174G) in IL6 were genotyped from 
490 participants of the DPS. 
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Interactions with physical activity 
Rs1800629 in TNF and rs1800795 in IL6 were not directly associated with changes in 
the levels of hs-CRP or IL–6 during the first year of the DPS. However, rs1800629 in 
TNF interacted with the 1-year change in moderate-to-vigorous physical activity on the 
1-year change in serum concentration of hs-CRP among those with high (≥3 mg/L) 
baseline levels of hs-CRP (p = 0.019, adjusting for age, gender, study group, baseline 
BMI and 1-year change in BMI). Those who carried the GG genotype of rs1800629 
decreased their serum levels of hs-CRP by increasing physical activity, whereas no such 
effect was seen in the carriers of the A-allele (Figure 11). There was no interaction 
between rs1800629 and moderate-to-vigorous physical activity among those with lower 
(<3 mg/L) baseline levels of hs-CRP (p = 0.973). No interaction with physical activity 
was found between rs1800795 in IL6 and changes in physical activity on the 1-year 
changes in serum hs-CRP or IL–6. 
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Figure 11. Changes of serum hs-CRP among genotypes of rs1800629 in 
TNF according to tertiles of change in moderate-to-vigorous physical 
activity during the first year of the Finnish Diabetes Prevention Study. 
Only the individuals with high (≥3 mg/L) baseline levels of hs-CRP are 
included (n = 127). Bars indicate adjusted mean of 1-year change in 
serum hs-CRP in each tertile of 1-year change in moderate-to-vigorous 
physical activity. Error bars indicate standard error of the mean. The 
values are adjusted for age, gender, study group, baseline hs-CRP, 
baseline moderate-to-vigorous physical activity, baseline body mass 
index (BMI), and 1-year changes in BMI. P-values are for the linear 
trend. p = 0.034 for the adjusted interaction between the change in 
moderate-to-vigorous physical activity and rs1800629. 
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In Study III, no interaction between the SNPs in TNF and IL6 and physical activity on 
the risk of type 2 diabetes, or changes in the components of metabolic syndrome (body 
weight, waist circumference, HDL cholesterol, triglycerides, or systolic blood pressure) 
was found. 
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VI DISCUSSION 
 
STUDY DESIGN AND SUBJECTS 
 
The identification and characterization of genes influencing the risk of complex 
multifactorial disease such as type 2 diabetes is a challenging task. However, 
unravelling the interactions between genes and lifestyle in the development of these 
conditions may be even more challenging. Firstly, most gene variants associated with 
common disease have only low or modest effects [13,14]. Secondly, lifestyle factors 
such as physical activity or dietary intake are difficult to quantify precisely [15-17]. 
Thirdly, several lifestyle and environmental factors confound the analyses. The 
detection of gene-lifestyle interactions thus requires large study populations and careful 
measurement of various lifestyle and environmental exposures. 
     In the present study, the interactions of physical activity with gene variants were 
analysed prospectively with type 2 diabetes as the clinical outcome. To our knowledge, 
no other studies have yet been performed with a similar analysis strategy. The study was 
based on the data of the Finnish DPS, a randomized controlled trial on the prevention of 
type 2 diabetes. The subjects were recruited from five participating centers, including 
Helsinki, Kuopio, Oulu, Tampere, and Turku [111,300]. All participants were 
overweight and met the WHO criteria for IGT twice, and were thus at a high risk of 
developing type 2 diabetes. The selection of high-risk individuals increases the 
statistical power for detecting interactions. However, the disadvantage is that there may 
be covert selection by genotype, limiting the generalisability of the results. The results 
also reflect fairly short-term metabolic responses in individuals who have already 
developed glucose abnormalities, and thus do not give information on how genetic 
factors increase the risk of type 2 diabetes over lifetime. 
     Sample size is a key determinant of the quality of a genetic association study [318]. 
The population in the present study included 507 participants of the DPS for whom 
genotype data were available. The size of the study was modest for an interaction study 
[254] and especially for SNPs with low minor allele frequencies [134]. The precision of 
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the methods used for measuring physical activity also plays an important role in 
detecting gene-physical activity interactions [15]. We assessed physical activity with a 
self-administered questionnaire, which is a fairly imprecise measure of physical activity. 
The statistical power of the present study is thus limited for investigating interactions. 
Furthermore, the original DPS used a multi-component intervention where physical 
activity, dietary changes, and weight loss were combined in a single intervention arm 
[300,304]. The yearly measurement of changes in diet, physical activity and body 
weight allowed statistical disentanglement for the other interventions [306]. Statistical 
adjustments do not, however, allow the evaluation of the independent role of physical 
activity to the same certainty as a randomised controlled trial containing an exercise-
only intervention. 
     Despite its limitations, the DPS provides a more powerful framework for the 
assessment of gene-physical activity interactions than cross-sectional epidemiological 
studies and many other prospective studies. The strengths of the present study lie on the 
randomized and controlled design of the DPS, the detailed assessment of physical 
activity using a validated questionnaire, and the repeated measurement of physical 
activity and other lifestyle exposures. As the present studies investigate, however, 
association and do not test cause and effect, the replication of genetic associations in 
independent large-scale study populations is critical. 
 
 
METHODS 
 
Diagnosis of diabetes 
The 1985 WHO criteria for diabetes [308] were used in all analyses of the present study 
despite newer criteria have been published in 1999 [1]. In the new criteria, the cut point 
of fasting glucose for the diagnosis of diabetes was lowered from 7.8 to 7.0 mmol/L, 
which could slightly affect our results. The 1985 criteria were, however, in use when the 
Finnish DPS was planned and through most of the trial itself, and all data on the DPS 
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have thus been published using them. Therefore, we used the same diagnostic criteria to 
maintain comparability with other published data in the DPS.  
 
Measurement of physical activity 
The self-reported data on physical activity was collected through the KIHD 
questionnaire (Appendix I) [305]. The questionnaire has provided valuable information 
on physical activity and health outcomes in the KIHD Study [319-322]. The validity of 
the questionnaire has been tested against VO2max [323], and the questionnaire is also 
quite repeatable [305]. Nonetheless, measurement error is still large. The yearly 
measurement of physical activity and the use of averaged physical activity levels during 
the follow–up, however, reduce measurement variability. Average physical activity 
values also reflect the actual levels of physical activity throughout the study better than 
a single follow-up measurement. The disadvantage is that there may be differential 
measurement error, as those individuals who did not develop diabetes were followed-up 
longer and were more likely to have multiple measurements. Physical activity is thus 
more precisely measured in these individuals, which may lead to slight underestimation 
or overestimation of our results [324].  
     Objective measurement of physical activity would have been desirable in the Finnish 
DPS, because it increases the precision of physical activity estimates [325]. However, it 
was not feasible at the time the DPS was carried out, and it would have been 
exceedingly expensive to assess changes in physical activity of individuals over time in 
a way that also accurately takes into account the substantial seasonal changes in 
physical activity patterns that occur in countries such as Finland that have four seasons. 
The rapid development of physical activity monitors will make objective measurement 
of physical activity viable in future trials. 
 
Measurement of dietary intake 
The intakes of total energy, fat, saturated fat, and fiber were used as covariates in the 
gene-physical activity interaction analyses, and they were measured by the 3-day food 
records. Although the precision of the food record method is likely sufficient for the 
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estimation of energy-adjusted macronutrient intakes [326], the dietary data was 
unfortunately available only from baseline and years 1, 2, and 3 of the intervention 
period, whereas physical activity data were available from all six years of the 
intervention. However, it has been shown that the dietary changes achieved during the 
first three years remained fairly constant even three years after the intervention period 
ended [327]. Therefore, the lack of dietary data from the latter years of the intervention 
should only slightly impair the accuracy of the analyses. 
 
Genotyping 
Three different methods were used for the genotyping of the candidate gene 
polymorphisms: PCR-SSCP, RFLP, and TaqMan assays. Although each method is 
widely used and reliable, the chance of genotyping errors cannot be neglected. A 
genotyping error rate of between 0.5% and 1% has been usual in many laboratories 
[328,329]. To avoid substantial genotyping errors and to calculate genotyping error rate, 
it has been recommended that 5-10% randomly chosen samples should be regenotyped 
[330,331]. In the DPS, we confirmed the accuracy of the genotyping of SNPs in the 
SCL2A2, ABCC8, TCF7L2, and GHRL genes by replicating a randomly selected subset 
of samples. Regenotyping of 6.0% of samples in the SLC2A2 and ABCC8 genes (Study 
II), 7.1% of the samples in the TCF7L2 gene [123], and approximately 10% of the 
samples in the GHRL gene [332] gave 100% identical results. With regard to rs1801282 
(Pro12Ala) of PPARG2, all the samples that were hetero- or homozygous for the Ala12 
allele were reanalysed to confirm the genotype [333]. However, there is no information 
on the genotyping errors or genotyping error rates for the other genes. A test for Hardy-
Weinberg equilibrium was, however, performed for each polymorphism, and a 
significant deviation from the equilibrium is often the result of genotyping errors [334]. 
Only one of the studied SNPs (rs2188966 in ABCC8) differed from Hardy-Weinberg 
equilibrium, and was thus omitted from all statistical analyses in Study II. 
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Selection of SNPs 
Although it is possible that interaction effects exist in the absence of detectable main 
effects, strong associations of both the measured lifestyle factor and the genetic variant 
with the outcome increases the likelihood of detecting interactions [254]. As the 
statistical power of the DPS was limited, we focused on physical activity that was 
strongly associated with the risk of developing type 2 diabetes in the DPS [170]. With 
regard to candidate genes, we mainly investigated such genetic variants which had been 
detected to be associated with the risk of type 2 diabetes in the DPS. This approach was 
supported by the finding that, for most of the genes associated with type 2 diabetes in 
the DPS, the association with the risk was more pronounced in either the intervention 
group [115-120] or the control group [114,119,121-123] of the DPS. This indicated that 
lifestyle changes modified the association of the polymorphisms with the incidence of 
type 2 diabetes. In Study IV, to avoid multiple testing, we performed a replication study 
on two SNPs in the TNF and IL6 genes that were shown to interact with physical 
activity on the serum levels of hs-CRP and IL-6 in previous studies [335,336]. 
Replication studies provide insurance against errors and biases that can afflict any 
individual study, and amplify confidence that the associations reflect processes that are 
biologically interesting rather than methodological inadequacies [134,337]. 
 
Statistical analyses 
In the Finnish DPS, participants in the intervention group achieved significantly greater 
lifestyle changes than individuals in the control group [304]. This was also seen as a 
58% reduction in the risk of developing type 2 diabetes [111]. However, in the physical 
activity analyses of the DPS we combined the intervention and control groups instead of 
analysing the groups separately. Combining study groups was necessary, as it gave a 
larger sample size and more power to detect interaction effects than a sub-group 
analysis. Combining the groups was also statistically plausible, as the difference 
between the intervention and control groups in the changes in physical activity was 
modest compared with the overall changes in physical activity, and changes in physical 
activity were associated with a lower risk of type 2 diabetes in both groups [306]. To 
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adjust for differences between two study groups we used the group assignment as a 
factor in the statistical models. 
     Absolute changes in physical activity were used in all our analyses instead of relative 
(%) changes in physical activity, and differences in the baseline level of physical 
activity were accounted for by adding baseline physical activity as a covariate in 
statistical models. The use of relative changes in physical activity would have had the 
advantage that it directly accounts for baseline differences in physical activity. 
However, the use of relative changes was not feasible in the present analyses, as 
individuals with very low physical activity values would, in some cases, have shown 
very large relative changes in physical activity, whereas the relative changes would 
have been small in the individuals with high baseline physical activity. Therefore, using 
absolute changes in physical activity with adjustment for the baseline physical activity 
was a more favourable option. 
     In the DPS, changes in total physical activity, but also in moderate-to-vigorous 
intensity physical activity and low-intensity physical activity, were associated with the 
incidence of type 2 diabetes [306]. In the present analyses, we mainly chose to study the 
interactions of gene variants with the changes in total and moderate-to-vigorous 
physical activity on the risk of type 2 diabetes or changes in metabolic outcomes. The 
low-intensity physical activity category was of less interest, as it is physiologically 
unlikely that an interaction with low-intensity physical activity would be apparent 
without an interaction with the total or moderate-to-vigorous physical activity that more 
likely has metabolic and other health effects [144,320,323,338]. Furthermore, the 
amount of low-intensity physical activity did not change in either study group of the 
DPS, indicating that changes in low-intensity physical activity did not explain the 
decrease in the incidence of type 2 diabetes brought about by the intervention [306]. 
The size of the DPS was also not sufficient to study the associations between different 
forms of physical activity [306] and genetic polymorphisms on clinical outcomes. 
     We used two different follow-up times in our analyses on gene-physical activity 
interactions. In particular, 1-year changes in physical activity were used to study 
interactions on the changes in the characteristics of metabolic syndrome and serum 
levels of hs-CRP and IL-6, whereas the total length of the follow-up was exploited with 
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regard to the analyses on the risk of type 2 diabetes. These follow-up times were chosen 
to increase statistical power for detecting interactions. Changes in the components of 
metabolic syndrome and in lifestyle were greatest during the first-year of the 
intervention of the DPS, and a slight relapse occurred towards the later years [327,339]. 
On the other hand, diabetes cases accumulated steadily over the whole length of the 
study [327]. Therefore, genotypic differences in the changes in characteristics of 
metabolic syndrome were most likely to be found during the first year of the 
intervention, whereas with regard to type 2 diabetes, the increase in the number of cases 
achieved during the whole length of follow-up was beneficial.  
     As the sample size of the DPS was modest, the power of the present study to detect 
differences in additive genotypic models (i.e. three genotypic groups of an SNP), and 
especially for SNPs with low minor allele frequencies, was limited. Therefore, in nearly 
all analyses, the subjects who were hetero- or homozygous for the rare allele were 
combined and compared with subjects who were homozygous for the common allele. 
This approach (the dominant model) may have led to the loss of some biological 
information, if the effect of the minor allele on the outcome was additive. 
     Finally, a large number of statistical tests were performed in the present study. The 
positive association of a genetic variant with the disease or the trait does not necessarily 
mean a causal relationship since the association can represent a false positive finding 
either randomly or, for example, due to selection bias. On the other hand, the absence of 
association does not necessarily indicate a true negative finding, but may result from the 
lack of power to detect an association. Therefore, to confirm that the observed 
associations are true, the results should be repeated in independent study samples. 
 
 
MAIN FINDINGS 
 
The main findings of the studies on the interaction of physical activity with genetic 
variants in the DPS are summarised in the Table 9. 
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Table 9. Summary of interactions of candidate genes with physical activity in the Finnish Diabetes Prevention Study. 
Gene Main finding Reference 
ADRA2B Increased physical activity did not decrease the risk of type 2 diabetes in the 
carriers of the risk genotype 
[340] 
PPARG Increased physical activity removed the effect of the risk genotypes on the 
risk of type 2 diabetes 
Study I 
SLC2A2, ABCC8 Increased physical activity removed the effect of the risk genotypes on the 
risk of type 2 diabetes 
Study II 
GHRL, LEPR The responses of BMI and HDL cholesterol (GHRL) or systolic blood pressure 
(LEPR) to changes in physical activity differed among the genotypes 
Study III 
TNF Physical activity lowered serum CRP only in the carriers of the common 
homozygous genotype 
Study IV 
Abbreviations: ABCC8, ATP-binding cassette, sub-family C (CFTR/MRP), member 8; ADRA2B, adrenergic receptor 
alpha-2B; BMI, body mass index; CRP, C-reactive protein; GHRL, ghrelin/obestatin prepropeptide; HDL, high-density 
lipoprotein; LEPR, leptin receptor; PPARG, peroxisome proliferator-activated receptor gamma; SLC2A2, solute 
carrier family 2 (facilitated glucose transporter), member 2; TNF, tumor necrosis factor (TNF superfamily, member 
2) 
 
The PPARG gene (Study I) 
In the Study I, we extended the previous analyses of the DPS on the Pro12Ala SNP in 
PPARG2 [114] by genotyping six additional SNPs from selected regions of PPARG. 
We showed that the carriers of the rare allele of rs17036314 or rs1801282 (Pro12Ala), 
which were part of the same haplotype block, had an increased risk of conversion from 
IGT to type 2 diabetes compared with the carriers of the common homozygous 
genotype. Furthermore, we showed that changes in physical activity during the 
intervention modified the effects of rs17036314 and rs1801282 on the risk of type 2 
diabetes. We also showed that the distinct rs1152003 SNP in the 3' flanking sequence of 
PPARG had an interaction with the lifestyle intervention of the DPS, and it was 
associated with a lower risk of type 2 diabetes in the intervention group, independent of 
rs1801282 (Pro12Ala) genotype. 
 
Associations with type 2 diabetes 
Unexpectedly, carriers of the Ala12 allele had an increased risk of type 2 diabetes 
compared with Pro12 homozygotes in the DPS (Study I) [114]. In contrast, the Ala12 
allele has been associated with increased insulin sensitivity and a moderately decreased 
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risk of type 2 diabetes in various populations [295]. In the largest meta-analysis among 
42,910 individuals, the Ala12 carriers had a 19% reduction in the risk of type 2 diabetes 
[341]. 
     Several factors may have modified the association of the Pro12Ala SNP with the risk 
of type 2 diabetes in the DPS. Apart from increasing the risk of type 2 diabetes, the 
Ala12 allele increases the risk of obesity, which may compromise its beneficial effects 
on insulin sensitivity [342]. Other sequence variants in PPARG2 may also modify the 
effect of the Pro12Ala SNP on these metabolic traits [343-346]. Variation in more than 
one haplotype block of PPARG is associated with improvements in insulin sensitivity 
with the PPARG agonist troglitazone [317], and it is logical to expect similar diversity 
with respect to PPARG and the risk of type 2 diabetes. Furthermore, particular 
coactivators or corepressors may modulate the effects of variants in PPARG [347]. 
Accumulating evidence also supports the role of PPARG2 as a mediator between 
lifestyle and the regulation of metabolism [278-281,296-299]. 
     The benefits of the Ala12 allele may also have been compromised by existing defects 
in insulin secretion among the participants of the DPS. Firstly, the earlier analyses of 
the DPS on the Pro12Ala SNP showed that the Ala12 allele was associated with the risk 
of type 2 diabetes particularly in the less obese half of the subjects (mean BMI 27.7 ± 
1.6 kg/m
2
), in whom the reason for IGT might more be related to impairments in insulin 
secretion than in insulin action [114]. Secondly, in Study II we also found that the Ala12 
allele was associated with higher fasting glucose at baseline, whereas a meta-analysis 
indicated a significantly lower fasting glucose concentration in the Ala allele carriers 
than in the Pro12 homozygotes among obese nondiabetic subjects [342]. Therefore, the 
association of the Ala12 allele with an increased risk of type 2 diabetes could be due to 
the selection of high-risk individuals with IGT, who already have a decreased insulin 
secretion capacity. PPARG has been shown to modify glucose-induced insulin secretion 
by activating the expression of GLUT2 and CAP1 genes in pancreatic β-cells [348], and 
a functional PPAR response element has been identified in the GLUT2 gene promoter 
[349]. The SNPs in the promoter region of GLUT2 were strongly associated with the 
risk of type 2 diabetes in the DPS [121]. 
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Interactions with physical activity 
In Study I, we showed that the carriers of the Ala12 allele were more responsive to 
changes in physical activity than the non-carriers in the DPS. The result is consistent 
with most of earlier studies. Altogether four studies have assessed the relationship 
between the Pro12Ala SNP and exercise-induced changes on insulin action [278-281]. 
All four studies indicated that the Ala12 allele carriers are more responsive to the 
insulin-sensitizing effect of exercise training. In sedentary Japanese men, three months 
of supervised exercise training improved insulin action more in six Ala12 allele carriers 
than in 117 Pro12 homozygotes [278]. Similarly, six months of supervised endurance 
training in sedentary men resulted in significantly greater decreases in fasting insulin 
and insulin area under the curve in an OGTT in Pro12Ala heterozygotes (n=8) 
compared with Pro12 homozygotes (n=24) [279]. In a study among 29 healthy first-
degree relatives of patients with type 2 diabetes, insulin sensitivity tended to improve 
more in the Ala12 carriers than in the Pro12 homozygotes in response to a 10-week 
training program, but not in 17 individuals without a family history of type 2 diabetes 
[281]. Three months of supervised exercise training was also associated with greater 
decreases in fasting plasma glucose levels in 139 patients with type 2 diabetes carrying 
the Ala12 allele in comparison to the Pro12 homozygotes [280]. However, in contrast to 
Study I, a recent cross-sectional study among 236 non-Hispanic whites from Colorado 
reported that the Ala12 allele was associated with a lower risk of type 2 diabetes only 
among the individuals with a lower level of physical activity [282], whereas in the DPS, 
the Ala12 allele was associated with a higher risk in the less active individuals. 
     The Ala12 allele of the Pro12Ala SNP replaces an amino acid in PPARγ2, a key 
transcription factor in the regulation of adipocyte differentiation. PPARγ2 is particularly 
expressed in white adipose tissue, and thus its effects on glucose homeostasis may be 
due to changes in adipose tissue metabolism [315]. Indeed, [350,351], although not all 
[352] studies have indicated that the Ala12 allele reduces the transcriptional activity of 
PPARG2, leading to an enhanced ability of insulin to suppress lipolysis in adipocytes. 
Lower amounts of FFAs are thus liberated into the circulation in Ala12 carriers [353]. 
The reduced availability of FFAs permits glucose to be preferentially oxidized as a fuel 
source in the skeletal muscle, thereby improving overall glucose homeostasis [354]. 
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Consistent with this hypothesis, a study among type 2 diabetics reported lower plasma 
FFA levels at baseline and after exercise training in the Ala12 carriers compared with 
Pro12 homozygotes [280]. 
     PPARG may also enhance glucose homeostasis through other mechanisms. Agonists 
of the PPARG gene increase the expression and plasma levels of adiponectin, a putative 
insulin-sensitizing hormone [355]. In a study among Finnish servicemen, significant 
increases in plasma adiponectin were seen in the carriers of the Ala12 allele after weight 
loss induced by heavy exercise [356]. However, increased adiponectin levels were 
detected only in individuals with a large weight loss (> 10%). The two studies that have 
examined the direct association between the Pro12Ala SNP and plasma adiponectin 
levels have produced inconsistent results [357,358]. 
     The functional PPAR response elements in the promoter of SLCA2 [349], and the 
interaction of both the PPARG and the SLC2A2 genes (Study II) with physical activity 
in the DPS support the notion that the interaction of both genes with physical activity 
could be mediated by effects on pancreatic insulin secretion [348]. Smaller amounts of 
PPARγ are present in extra-adipose tissues that are central to glucose homeostasis, 
including skeletal muscle and liver [359]. Furthermore, the expression of PPARγ in 
macrophages may be important in the development of obesity-related insulin resistance 
[360]. The pathophysiological importance of PPARγ in these tissues is currently 
unknown. 
 
Interaction with lifestyle intervention 
Rs1152003 in the 3' flanking region of PPARG is distinct from any other haplotype 
block in PPARG, and has been associated with troglitazone response in 93 non-diabetic 
Hispanic women [317]. In the present study, rs1152003 was associated with a decreased 
risk of type 2 diabetes in the intervention group, independently of rs1801282 
(Pro12Ala) genotype. Rs1152003 was also associated with fasting glucose 
concentration at baseline. This SNP may thus be an important mediator of the effect of 
PPARG agonist treatment or lifestyle modification on glucose homeostasis and the risk 
of type 2 diabetes. However, in the DPP, no difference between rs1152003 genotypes in 
the response to troglitazone treatment was found [361]. More studies on the association 
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of rs1152003 with type 2 diabetes and its possible interactions with lifestyle and 
troglitazone treatment are required to draw more reliable conclusions. 
 
The SLC2A2, ABCC8, and KCNJ11 genes (Study II) 
In Study II, we analyzed the interactions of SNPs in three genes regulating insulin 
secretion, including SLC2A2, ABCC8, and KCNJ11 with physical activity on the 
incidence of type 2 diabetes. In previous analyses of the DPS, SNPs in SLC2A2 and 
ABCC8, but not in KCNJ11, were associated with the risk of progression from IGT to 
type 2 diabetes [119,121]. However, the lifestyle intervention decreased the risk 
associated with the specific genotypes [119,121]. In the present study, we detected 
significant interactions between SNPs in SLC2A2 and ABCC8 with moderate-to-
vigorous physical activity on the conversion from IGT to type 2 diabetes in the DPS. 
 
Interactions with physical activity 
No other studies on the interaction of the SLC2A2 and ABCC8 genes with physical 
activity on the risk of type 2 diabetes have been published. Both genes have an essential 
role in glucose-induced insulin secretion from the pancreatic β–cells [362,363]. SLC2A2 
encodes glucose transporter 2 (GLUT2), a facilitative glucose transporter that affects 
insulin secretion by regulating the entry of glucose into the pancreatic β–cell. ABCC8 
encodes sulfonylurea 1 receptor (SUR1), and KCNJ11 encodes K+ inward rectifier 
(Kir6.2), the two subunits of the pancreatic ATP-sensitive potassium (KATP) channels.  
KATP channels regulate insulin secretion by coupling β–cell glucose metabolism to 
membrane potential. The activity of the channels is inhibited by ATP, and as the ATP 
concentration in the β–cells increases due to increased glucose metabolism, the cell 
membrane becomes depolarized thereby triggering insulin exocytosis. 
     SNPs in SLC2A2 and ABCC8 modify insulin secretion [364-368]. Therefore, a 
differential genotypic response in β–cell function to changes in physical activity is the 
most likely explanation for their interaction with physical activity on the incidence of 
type 2 diabetes. It is now known that the transition from normal glucose tolerance 
through IGT to full-blown diabetes is characterized by a progressive decline of β–cell 
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function [369]. Only few studies have investigated the effects of lifestyle interventions 
on insulin sensitivity and insulin secretion in persons with IGT [45,370]. In the DPS, 
based on a repeated frequently sampled intravenous glucose tolerance test (FSIGT), 
insulin sensitivity improved along with lifestyle changes while insulin secretion 
remained virtually unchanged [45]. Most other data also indicate that lifestyle changes 
primarily increase insulin sensitivity. However, the glycemic stress that is associated 
with insulin resistance may exhaust β–cells and impair their function. By improving 
insulin sensitivity, regular physical activity reduces glycemic stress and thus indirectly 
protects β–cells [20,371]. Furthermore, some studies suggest that physical activity 
[250,251], diet [372,373], weight loss [374], or their combination [370] may directly 
improve the first-phase insulin secretion, which is an indicator of the β–cell function. 
     We found no interaction between the changes in physical activity and the SNPs in 
SLC2A2 and ABCC8 on changes in fasting or 2-hour insulin levels. However, insulin 
levels are strongly regulated by insulin resistance and are thus not reliable indicators of 
early insulin secretion. Because 30 min insulin, the insulinogenic index, or other more 
precise measures of early insulin secretion were not available in Study II, differences in 
the changes in β–cell function between genotypes could not be assessed. 
     As SLC2A2 and ABCC8 are not exclusively expressed in pancreas, it is possible that 
their interaction with physical activity could be mediated by effects in extra-pancreatic 
tissues. SLC2A2 is expressed in hepatocytes where GLUT2 participates in liver glucose 
uptake and release [362]. In addition, it is expressed in intestinal and renal cells, where 
it is involved in intestinal glucose absorption and renal glucose reabsorption. SUR1, 
encoded by ABCC8, is abundant in KATP channels in many regions in the brain, and 
particularly in the hypothalamus [375]. The activation of KATP channels in the 
mediobasal hypothalamus inhibits hepatic gluconeogenesis, suggesting that the effects 
of ABCC8 are partly centrally mediated [376]. Interestingly, in a genome-wide linkage 
scan, based on the HERITAGE Family Study, a marker within ABCC8 exhibited one of 
the most significant linkages to maximal oxygen uptake in the sedentary state [377]. 
     The E23K SNP of KCNJ11 was not associated with the risk of type 2 diabetes in the 
DPS [92], and did not interact significantly with physical activity in Study II. 
Consistently, the DPP study did not detect an interaction between the E23K SNP and 
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lifestyle changes on the progression to type 2 diabetes [128]. It is thus likely that the 
association of the E23K SNP with type 2 diabetes is not modified by lifestyle changes. 
     The interaction of physical activity with genes regulating insulin secretion in the 
DPS suggests that physical activity not only improves insulin sensitivity, but may also 
preserve β–cell function. There are, however, limited data on direct effects of physical 
activity on β–cell function. Therefore, the interaction of SLC2A2 and ABCC8 with 
physical activity may be due to an indirect effect. Physical activity improves insulin 
sensitivity, which slows the progressive decrease in β–cell functioning in the 
progression from IGT to type 2 diabetes. 
 
The ADRB2, ADRB3, IGF1R, LIPC, LEPR, GHRL, and TCF7L2 genes 
(Study III) 
In the Study III, we showed that the Leu72Met (rs696217) SNP of GHRL modified the 
effect of moderate-to-vigorous physical activity on the changes in weight and waist 
circumference, the –501A/C (rs26802) SNP of GHRL modified the effect of total and 
moderate-to-vigorous physical activity on the change in HDL cholesterol concentration, 
and the Lys109Arg (rs1137100) SNP of LEPR modified the effect of total physical 
activity on the change in systolic blood pressure. No interaction was found between 
variants in ADRB2, ADRB3, IGF1R, LIPC, or TCF7L2 and physical activity on the risk 
of type 2 diabetes or changes in characteristics of the metabolic syndrome. 
 
GHRL Leu72Met and body weight 
Increased physical activity resulted in a decrease in body weight and waist 
circumference in the carriers of the Met72 allele but not in the Leu72 homozygotes of 
GHRL. There are no earlier reports available on the interaction between variants in 
GHRL and physical activity on changes in body weight. Ghrelin binds to the growth 
hormone (GH) segretagogue receptor, releasing GH into the systemic circulation [378]. 
Increased GH release through ghrelin action could increase lipolysis and thus lead to 
decreased adiposity [379]. Ghrelin is also known to stimulate appetite and increase food 
intake, and thereby affect energy balance [380]. Ghrelin levels increase in relation to a 
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decrease in body weight, acting possible as a compensatory signal to restore body 
weight.  
     Similarly as ghrelin, physical activity of moderate-to-vigorous intensity stimulates 
GH release [381]. However, acute exercise does not seem to affect ghrelin 
concentrations [382], and long-term aerobic exercise training increases ghrelin levels 
only when weight loss is produced [383,384]. Although there was no effect on total 
ghrelin levels, a 5-day aerobic exercise program was reported to increase the proportion 
of biologically active, acylated ghrelin in blood [385]. Ghrelin circulates in both 
acylated and deacyl forms, but only the acylated ghrelin binds to the GH segretagogue 
receptor, affecting GH release and energy balance [386]. Furthermore, two studies have 
reported that changes in ghrelin levels were associated with changes in fat-free mass, 
but not in fat mass during weight loss [387,388]. By maintaining or increasing fat-free 
mass, physical activity could indirectly affect total ghrelin levels. The Leu72Met SNP 
has been associated with ghrelin levels in some studies with Met72 allele carriers 
showing the highest total [389] or acylated ghrelin concentrations [390] and other 
showing a trend for high total ghrelin levels with Met72 allele carrier status [391,392] 
or no association [393,394]. Unfortunately, ghrelin levels were not measured in the 
DPS. 
     Interestingly, the baseline level of total physical activity differed among the 
genotypes of the Leu72Met SNP of GHRL, suggesting that the carriers of the Met72 
allele may adopt a higher level of activity than those homozygous for the Leu72 
genotype. Indeed, studies in rats indicate that centrally administered ghrelin decreases 
spontaneous physical activity [395]. The Leu72Met SNP did not, however, have a 
significant effect on the change in physical activity during the follow-up.  
 
GHRL -501A/C and HDL-cholesterol 
Increased physical activity led to an increase in serum HDL cholesterol in the AA 
homozygotes of the -501A/C SNP of GHRL, whereas no such changes were found 
among the carriers of the C allele. Physical activity is known to increase serum levels of 
HDL cholesterol, but there is a large inter-individual variability in the response [396]. 
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Gene variants that modify the effect of physical activity on HDL cholesterol are 
currently unknown. 
     The interaction between the -501 A/C SNP and physical activity on serum HDL 
cholesterol is a novel finding. Three studies have, however, reported a positive 
correlation between plasma ghrelin and HDL cholesterol [397-399], and one study 
reported an association between the -1062 G/C SNP in the promoter of GHRL and HDL 
cholesterol [400]. The -501A/C SNP has been associated with the rate of ghrelin mRNA 
expression [401,402]. It has been suggested that HDL particles may have a role as 
circulating ghrelin transporters [403]. Recent studies also indicate that ghrelin analogs 
may affect cholesterol metabolism through binding CD36 and GH segretagogue 
receptors on macrophages, leading to cholesterol efflux into the HDL reverse pathway 
[404]. Further studies are needed to elucidate the mechanisms behind the association of 
ghrelin with HDL cholesterol. 
 
LEPR Lys109Arg and blood pressure 
Increase in physical activity led to a decrease in blood pressure only in carriers of the 
Lys109Lys genotype of LEPR, whereas the carriers of the Arg109 allele did not respond 
to physical activity. No other reports exist on the interaction between variants in LEPR 
and physical activity on blood pressure. However, a differential response to a 3-month 
lifestyle modification of caloric restriction and moderate physical activity among the 
genotypes of the Lys656Asn SNP of LEPR has been reported [405]. Systolic blood 
pressure decreased significantly in the Lys656 homozygotes, but not in the carriers of 
the Asn656 allele [405]. The Lys109Arg SNP has also reported to modify the effect of a 
20-week endurance training program on measures of glucose homeostasis in the 
HERITAGE Family Study [260]. 
     Leptin is an adipocyte-secreted hormone that is mainly involved in the regulation of 
energy homeostasis [406]. However, it may also affect blood pressure by stimulating 
sympathetic outflow [407,408]. High circulating levels of leptin may partly explain the 
increase in renal sympathetic tone observed in obese people [409]. Exercise training 
alone or in combination with dietary modification has been reported to decrease serum 
leptin levels independently of weight loss [410,411]. A sequence variation in LEPR 
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might impair the effect of leptin on its receptor, attenuating the favourable effect of 
physical activity on blood pressure. Indeed, polymorphisms in LEPR have been 
associated with high plasma leptin levels indicating leptin resistance, and a lower 
whole-body plasma norepinephrine spillover, an index of blunted sympathetic nerve 
activity [412]. 
     In the HERITAGE Study, the Lys109Arg SNP of LEPR has also been shown to 
modify the effect of 20 weeks of aerobic exercise training on glucose homeostasis 
among 397 nondiabetic whites [260]. We did not detect interactions between SNPs in 
LEPR and changes in physical activity on the risk of progressing from IGT to type 2 
diabetes. However, the interaction of physical activity with the LEPR gene could be 
observed only in healthy individuals [260], and not in persons with IGT who are at a 
relatively late stage in the pathogenesis of type 2 diabetes. In the HERITAGE, the effect 
of the LEPR gene was also modified by variation in the LEP gene [260]. We did not 
investigate the effects of SNPs in LEP on the incidence of type 2 diabetes in the DPS. 
 
The LIPC and ADRB2 genes 
No interaction between the G-250A SNP of LIPC and physical activity was observed, 
although the -514C/T variant of LIPC has been associated with training-induced 
improvements in insulin sensitivity in 443 white men and women participating in the 
HERITAGE Study [275]. We did not genotype the -514 C/T SNP in the DPS. The G-
250A SNP was, however, strongly associated with the conversion from IGT to type 2 
diabetes in the DPS, and there was an interaction with the lifestyle intervention. This 
indicates that LIPC may interact with lifestyle changes. Our study may have been 
underpowered to detect an interaction with physical activity on the incidence of type 2 
diabetes. Therefore, further studies are required to show whether variation in LIPC 
modifies the responses of glucose homeostasis to lifestyle changes. 
     Variants in ADRB2 have reported to modify changes in body weight in response to 
physical activity in three separate studies [262-264]. In the DPS, we did not find an 
interaction between the Gln27Glu of ADRB2 and physical activity with regard to 
changes in BMI. The results from the earlier studies are, however, also inconsistent with 
respect to specific variants that have modified the responses, and with regard to the 
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effect of gender. In the initial cross-sectional study of 836 French men and women, 
body weight, waist circumference, and waist-to-hip ratio were higher in physically 
inactive men carrying the Glu27 allele of ADRB2 than in inactive men carrying other 
genotypes, whereas no significant difference between the genotypes was found among 
men who were physically active [262]. No similar interaction was found among women 
[262]. In the following case-control study among 139 obese Spanish women and 113 
healthy controls, the carriers of the Glu27 allele who were active in their leisure-time, 
had a higher BMI than other individuals with the same level of activity, whereas no 
difference between the genotypes was seen among the inactive individuals [263]. In the 
third study, the responses of ADRB2 genotypes to a 20-week endurance training 
program were followed among 482 white and 260 black participants [264]. The white 
women who were homozygous for the Gly16 allele of ADRB2 decreased their BMI, fat 
mass, and percent body fat more during the endurance training program than individuals 
with other genotypes [264]. However, no difference in the responses to the training 
program were found among the genotypes of the Glu27Gln SNP. These conflicting 
results between the three earlier studies and the negative result from the DPS leave it 
unsettled as to whether variation in the ADRB2 gene modifies the effect of physical 
activity on BMI. 
 
The TNF and IL6 genes (Studies III & IV) 
In Study IV, we found that rs1800629 (G-308A) SNP of TNF modified the effect of 
moderate-to-vigorous physical activity on the serum levels of hs-CRP among the 
individuals with high (≥3 mg/l) baseline levels of hs-CRP. The carriers of the GG 
genotype of rs1800629 achieved greater decreases in hs-CRP by increasing their 
moderate-to-vigorous physical activity than the carriers of the A allele. We did not find 
an interaction between rs1800795 (C-174G) of IL6 and physical activity on changes in 
serum IL-6. In Study III, there was no interaction between the SNPs of the TNF and IL6 
genes and physical activity on the risk of type 2 diabetes, or on characteristics of the 
metabolic syndrome. 
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     The interaction of rs1800629 with physical activity in the DPS replicates the finding 
from the HERITAGE Study, where only the carriers of the G allele were able to 
decrease their serum levels of hs-CRP in response to a 20-week exercise program [335]. 
In both studies, the gene-physical activity interaction was found among the individuals 
with high baseline levels of hs-CRP. In the HERITAGE Study, exercise was effective in 
reducing hs-CRP levels only among those with high baseline levels of hs-CRP [314]. 
Increased circulating levels of markers of low-grade inflammation, such as hs-CRP and 
IL-6, are associated with an increased risk of type 2 diabetes [413,414]. Modulation of 
the levels of inflammatory mediators may be one important approach to prevent type 2 
diabetes. In the DPS, moderate-to-vigorous intensity physical activity was significantly 
correlated with decreases in hs-CRP and IL-6 [415]. The interaction of TNF with 
physical activity on levels of hs-CRP in Study IV suggests that the anti-inflammatory 
effect of physical activity in the DPS may have depended on the genetic variation. The 
TNF gene encodes TNF-α, a proinflammatory cytokine that stimulates CRP production 
[232]. Rs1800629 is located in the promoter region of TNF, and has been shown to 
modify the transcription-rate of TNF. Compared with the A allele, the GG genotype of 
rs1800629 halves the transcription-rate of TNF [416]. Physical activity may also 
suppress TNF-α production by increasing the synthesis of IL-6 in the skeletal muscle 
[236], and via other, IL-6 independent mechanisms [244,249]. The interaction between 
rs1800629 and physical activity on serum hs-CRP may thus be mediated by their 
combined effect on the production of TNF-α. However, since we did not measure 
circulating TNF-α due to the limited availability of serum in the DPS, further studies are 
necessary to elucidate the mechanism. 
     In Study III, we found no interaction between physical activity and rs1800629 on the 
incidence of type 2 diabetes or changes in components of the metabolic syndrome. The 
combined evidence from Studies III and IV thus suggest that changes in hs-CRP do not 
clearly seem to turn into benefits with regard to components of the metabolic syndrome 
and type 2 diabetes. The studies do not, however, exclude the relationship between hs-
CRP and the metabolic syndrome or type 2 diabetes, because the interaction on hs-CRP 
levels was only found in individuals with high baseline levels of hs-CRP. An earlier 
report on the effects of rs1800629 among 56 sedentary 50- to 75-year old men and 
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women revealed interactions with 24 weeks of exercise training on glucose area under 
the curve and serum HDL cholesterol [273,417]. 
     We did not replicate the earlier finding on the interaction between rs1800795 in IL6 
and physical activity on the serum levels of IL-6 in individuals with IGT [336]. The 
most likely reasons for this are that earlier findings may be false positive, because the 
study was based on a very small sample of individuals (n = 24). The changes in physical 
activity in the DPS may also not compare well with the 20-week aerobic exercise 
training program (2 x 60 min of exercise per week) used in the previous study, or the 
simultaneous lifestyle changes (diet, weight reduction)  in the DPS may modify our 
results. Further studies on the interaction between rs1800795 and physical activity are 
required to confirm these findings.  
 
 
CONCLUDING REMARKS 
 
These secondary analyses of the Finnish DPS indicate that variation in genes regulating 
both insulin sensitivity (PPARG2) and insulin secretion (SLC2A2, ABCC8) interact with 
changes in physical activity on the risk of developing type 2 diabetes. Furthermore, 
variation in LEPR, and GHRL may modify the effects of physical activity on changes in 
features of the metabolic syndrome, and variation in TNF may modify the effect of 
physical activity on changes in serum hs-CRP levels. These findings give novel 
information on the interaction between physical activity and genetic variants in the 
etiology of type 2 diabetes and related traits in a prospective study setting. The results 
may be important in the ongoing effort to identify individuals at increased risk of 
developing type 2 diabetes and the metabolic syndrome, and those who are most likely 
to have enhanced health benefits from regular physical activity. However, the study was 
limited by its observational study design, a relatively low number of subjects, multiple 
statistical testing, and the non-objective measurement of physical activity. 
     During recent years, the genetics of type 2 diabetes has taken a leap forward, and the 
first robust evidence of diabetes susceptibility genes has been generated through 
genome-wide association studies. Studies investigating interactions between genes and 
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lifestyle are, however, generally even more challenging than the studies of genetic main 
effects, and reliable evidence is yet to be obtained. In the coming years, robustness of 
gene-physical activity interaction analyses can be improved by performing larger-scale 
studies with objective measurement of physical activity and by combining data from 
several studies into a meta-analysis. Sophisticated analytical approaches may be 
necessary to avoid false discoveries. The use of Bayesian approaches, based on the clear 
specification of prior probabilities of interaction, may be advantageous [17,337,418]. 
Increasing knowledge on gene function will help to identify the causal variants. With 
regard to the Finnish DPS, important steps have already been taken, as the DPS data 
will be combined with other data from intervention trials within the ongoing Integrated 
Project InterAct (www.inter-act.eu). The InterAct is a collaborative effort of 35 partners 
in 10 countries, aiming to discover how diet and physical activity interact on the risk of 
developing type 2 diabetes. By pooling the data, the InterAct may be the first study to 
achieve sufficient statistical power to generate robust evidence on gene-lifestyle 
interactions in the development of type 2 diabetes. 
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VII SUMMARY 
 
The main findings in Studies I-IV were: 
 
Study I 
The haplotype block containing the Pro12Ala SNP of PPARG2 increased the risk of 
type 2 diabetes, but an increase in physical activity removed the effect of the risk 
alleles. Furthermore, the lifestyle intervention of the DPS modified the association of an 
SNP in the 3' flanking region of PPARG with the risk of type 2 diabetes. The interaction 
of PPARG2 with physical activity is supported by previous literature, but the 
mechanisms remain unclear. The interaction of rs1152003 with lifestyle changes has not 
been previously reported, but is consistent with an earlier study on the association of 
rs1152003 with responsiveness to rosiglitazone treatment. 
 
Study II 
Moderate-to-vigorous physical activity modified the risk of developing type 2 diabetes 
associated with SLC2A2 and ABCC8. The interaction of physical activity with genes 
regulating insulin secretion suggests that physical activity not only improves insulin 
sensitivity but also preserves β–cell function. However, physical activity has not been 
shown to modify the function of SLC2A2 and ABCC8, and there is limited evidence of a 
direct effect of physical activity on β–cell function. Therefore, the interaction between 
SLCA2 and ABCC8 and physical activity may reflect the relationship between insulin 
sensitivity and β–cell function in the development of type 2 diabetes. Physical activity 
improves insulin sensitivity and thus also slows the progressive decrease in β–cell 
function. 
 
Study III 
No interaction between SNPs in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and 
GHRL with physical activity on the risk of developing type 2 diabetes was found. 
However, SNPs in LEPR and GHRL modified the effect of physical activity on changes 
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in systolic blood pressure (LEPR), and on changes in body weight, waist circumference, 
and concentration of HDL cholesterol (GHRL). The results indicate that genetic 
variation in LEPR and GHRL may modify the magnitude of beneficial effects of 
physical activity on the characteristics of the metabolic syndrome in individuals with 
IGT. Nonetheless, multiple statistical tests were performed and the detected interactions 
were not strongly suggested by previous literature. 
 
Study IV 
Physical activity modified the effect of rs1800629 (G-308A) in TNF on changes in 
serum levels of hs-CRP. The finding is consistent with a previous exercise training 
study. The interaction between rs1800629 and physical activity may be mediated by 
their combined suppressing effect on the production of TNF-α in the adipose tissue. 
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